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BDNF (brain-derived neurotrophic factor) plays an important role in neuronal survival, growth and 
maintenance of several neuronal systems, serves as neurotransmitter modulator and participates in 
plasticity important for learning and memory. BDNF is widely expressed in the CNS, beginning early in 
development and extending throughout life. In the mammalian brain, it is most abundant in the 
cerebral cortex and hippocampus. BDNF is of special interest because of the regulation of its 
expression and release as a function of the state of neuronal activity. In humans the most direct link 
between BDNF and pathological conditions is the recent discovery that the loss of one BDNF allele 
causes a strong obesity phenotype. In addition, there is accumulating evidence that in conditions such 
as Huntington (HD) decreased levels of BDNF may contribute to the disease. Finally, it is also 
associated with depression and anxiety. One key difficulty in understanding the role of BDNF in the 
adult brain has been the generation of suitable animal models as the germline deletion of BDNF leads 
to early postnatal death. To circumvent this difficulty, we generated conditional mutant mice in which 
BDNF is eliminated from the CNS through the use of the Cre-loxP recombination system. This was 
achieved by crossing 2 existing mouse lines, one carrying two floxed BDNF alleles and the other 
expressing Cre from the tau locus. Our results indicated that such conditional BDNF knockout mice 
(cbdnf ko) can survive for several months after birth with almost no detectable BDNF in their brain. 
This creates a novel opportunity to ask the general question of the role of BDNF in the adult CNS. 
Histological analysis indicated that the brain of these mutant mice is generally smaller, but in an 
unexpected region-specific manner affecting mostly the striatum and surprisingly not the hippocampus. 
The marked reduction in the volume of the striatum could not be explained by cell loss, defects of 
axonal diameter or hypomyelination, but most likely by a marked reduction in the volume of striatal 
neurons and their processes, which is currently quantified. The lack of hippocampal volume reduction 
could not be explained due to compensatory changes in the expression levels of NT4 and/or NT3.  It 
thus seems that the postnatal increase of BDNF may be essential for the growth of striatal neurons, 
and perhaps other GABAergic neurons, but not for hippocampal pyramidal neurons. At the 
behavioural level cbdnf ko animals exhibit a variety of defects, including a clasping phenotype similar 
to that observed in mouse models of Huntington’s disease.  
 
The cbdnf ko mice also provided a key control for parallel studies examining the biosynthesis, 
processing and storage of endogenous BDNF in the CNS. We showed that in hippocampal neurons 
pro-BDNF is a transient intermediate that is converted intracellularly to the mature form of BDNF, 
which is stored and released by excitatory input (Matsumoto et al., 2008).  
 
The new bdnf mutant animals generated during the course of this PhD thesis thus represent a new 
opportunity to study the role of BDNF in the adult mouse nervous system. 
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MEK    MAPK/ERK kinase 
mGluR   metabotropic glutamate recepor 
mRNA   messenger ribonucleic acid 
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MMP    matrix metalloproteinase 
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1.1. Neurotrophin family 
A hallmark of vertebrate evolution is the development of a complex nervous 
system. The enormous number of neurons makes coordination solely by cell 
intrinsic programs unfeasible. A common design principle in vertebrates is the 
sculpting of the nervous system during embryonic development from an initial 
excess of neurons with the elimination of the apparently redundant ones. Along 
with cell-intrinsic mechanisms, the final number is attained via degeneration of 
those neurons that fail to interact successfully with their intended targets. 
Specifically, they might fail in competition with their peers for survival signals in 
the form of secreted proteins that are provided in limited amounts by the target 
tissue. By this means, the number of innervating neurons is adjusted to the target 
tissue. Following the establishment of neuronal populations, neuronal processes 
are believed to grow or retract throughout ontogeny again as a function of target-
derived support. This organizing principle, which became known as the 
“neurotrophic theory” (Purves, 1988), allows the nervous system to flexibly adjust 
to bodily changes in size and form via rather simple regulatory loops with a 
minimum of genetic instructions. This theory is generally recognized as one of 
the important principles explaining the development of the nervous system in 
vertebrates. Central to this concept was the identification and characterization of 
secreted proteins known as neurotrophic factors that act as intercellular survival 
signals between target tissue and neurons. Nerve growth factor (NGF) was not 
only the first neurotrophic factor but also the first polypeptide growth factor to be 
identified (Cohen and Montalcini, 1956) and has become a paradigm for trophic 
factor research. Brain-derived neurotrophic factor (BDNF) was purified as the 
second member of the neurotrophin family (Barde et al., 1982) and with the 
cloning of neurotrophin-3 (NT3) (Ernfors et al., 1990; Hohn et al., 1990; Jones et 
al., 1990; Maisonpierre et al., 1990; Rosenthal et al., 1990) and neurotrophin 4/5 
(NT4/5) (Berkemeier et al., 1991; Ip et al., 1994) the small familiy of 
neurotrophins in higher vertebrates was complete.  
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Neurotrophins are initially synthesized as pre-pro-proteins by neuronal and non-
neuronal cell types and the mature proteins, which are about 12-14 kDa in size, 
form stable, non-covalent dimers, and are expressed at very low levels. The pro-
domain of the pro-neurotrophin is thought to be important for the proper folding 
and intracellular sorting of neurotrophins (also see below).  
 
The members of the neurotrophin family show different binding specifity for two 
classes of receptor: the Trk (tropomyosin receptor kinase) family of RTKs 
(receptor tyrosine kinases) and the p75 neurotrophin receptor (p75NTR). Upon 
ligand binding, Trk receptors dimerize and become catalytically active, resulting 
in receptor autophosphorylation and subsequent activation of a number of 
signaling cascades, including the Ras/Raf/MAPK (mitogen-activated protein 
kinase) (Thomas et al., 1992), PI3K (phosphoinositide 3-kinase) (Atwal et al., 
2000), and phospholipase C-γ 1 pathways (Vetter et al., 1991). Trk receptor 
subtypes bind mature neurotrophins with different specificities: TrkA preferentially 
binds NGF, TrkB preferentially binds BDNF and to a lesser extent NT3 and NT4, 
while TrkC displays preference for NT3. p75NTR binds all mature neurotrophins 
with approximately equal affinity and has, in recent years, been demonstrated to 
bind the proneurotrophins with higher affinity (Lee et al., 2001). p75NTR can also 
interact with a number of receptors, including the Trks (Bibel et al., 1999), sortilin 
(Nykjaer et al., 2004), and NOGO (Bandtlow et al., 2004), and is capable of 
binding ligands other than the neurotrophins, e.g. the β-amyloid (Yaar et al., 
1998) and prion peptides (Della-Bianca et al., 2001). Signaling mediators 
activated subsequent to p75NTR ligand binding include ceramide (Dobrowsky et 
al., 1994), NF-κB (nuclear factor κB) (Carter et al., 1996), Akt (also called protein 
kinase B) (Roux et al., 2001), JNK (c-Jun N-terminal kinase) (Friedman, 2000) 
and cysteine proteases termed caspases (Coulson et al., 2000). The complexity 
of this multiple ligand, multiple receptor signaling system is evidenced by the 
opposing actions of the neurotrophins. For example, Trk receptors are widely 
reported to promote cell survival, enhancement of process elongation and of the 
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efficacy of synaptic transmission, while strong evidence exists in support of a role 
for p75NTR in mediating inhibition of process elongation and cell death. 
 
1.2    BDNF 
 
1.2.1 BDNF gene, mRNA and protein 
 
Brain-derived neurotrophic factor (BDNF) was identified as a second member of 
the neurotrophin growth factor family with close structural homology to NGF 
(Barde et al., 1982; Leibrock et al., 1989). The mouse BDNF gene (AY057907) 
has a complex structure and consists of 8 exons with only exon 8 being a protein 
coding exon. The other 5′ exons contain different promoters so that all splice 
variants mBDNF 1, 2, 3, 4, 5 and 6A were reported to result in the expression of 
the same protein encoded by exon 8. Exon 2 displays two intraexonic splice sites 
giving rise to three different mBDNF 2 subvariants called mBDNF 2A, 2B and 2C. 
In addition, a three-part transcript, mBDNF 6B is the result of splicing events 
incorporating exons 6, 7 and 8, so that altogether 9 different splicing variants 
could be detected (Liu et al., 2006). Most of these splice variants were found in 
different regions of the brain and additionally some of them in other peripheral 
organs including the heart, lung, muscle, kidney, liver, testis, and spleen. 
However, the functional relevance of these different splice variants remains 
unclear (Liu et al., 2006). It has been reported that the different promotors for the 
splice variants are localized in two clusters with one cluster encompassing exons 
I, II and III (covering splice variants 1, 2A, 2B, 2C and 3) whereas the second 
cluster encompasses exons IV, V and VI (covering splice variants 4, 5, 6A and 
6B) (Liu et al., 2006). For cluster 2, some transcriptional regulatory elements that 
recognize calcium-responsive transcription factor (CaRF), cAMP/calcium-
responsive element binding proteins (CREB) and methyl-CpG binding protein 2 
(MeCP2) were described (Chen et al., 2003; Martinowich et al., 2003; Tao et al., 
2002). Northern blot experiments revealed approximately equimolar amounts of 
two BDNF transcripts of about 1.6 kB and 4.2 kB in the brain. Hybridization with a 
probe from the 3`UTR of the coding exon showed that the main difference in the 
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length of the two transcripts is due to an alternative use of two polyadenylation 
sites in the 3`UTR of the coding exon (Hofer et al., 1990; Maissonpierre et al., 
1990; Timmusk et al., 1993). In situ hybridization experiments have revealed that 
BDNF mRNA is strongly expressed in the brain. BDNF expression levels are low 
during fetal development, markedly increase after birth and then reduce to adult 
levels (Maisonpierre et al., 1990). In the adult animal, BDNF is expressed 
throughout the brain with the highest levels in the hippocampus, where BDNF 
mRNA was localized to pyramidal neurons of the CA1-CA3 regions and in 
granule cells of the dentate gyrus. Some CNS structures, such as the striatum 
and the spinal cord in particular express very low levels of BDNF mRNA (Hofer at 
al., 1990).   
 
BDNF mRNA expression is regulated by neuronal activity. For example, 
epileptogenic activation of glutamatergic synapses increased the expression of 
BDNF mRNA in slices of rat hippocampus (Ernfors et al., 1991; Zafra et al., 
1990), and increasing synaptic activity with AMPA receptor agonists induced a 
transient elevation in mRNA levels encoding BDNF and TrkB in the hippocampus 
and entorhinal cortex (Lauterborn et al., 2000). Conversely, reduction of electrical 
activity by blockade of glutamate receptors or stimulation of the GABAergic 
system reduced BDNF mRNA level in the hippocampus (Zafra et al., 1991). 
These studies demonstrate that an increase or a decrease of neuronal activity 
can enhance or reduce BDNF expression. Consistent with these observations 
light-induced physiological activity enhanced the expression of BDNF mRNA in 
the visual cortex and monocular deprivation elicits a striking decrease in BDNF 
mRNA in the visual cortex corresponding to the deprived eye (Bozzi et al. 1995; 
Rossi et al. 1999; Lein and Shatz 2000). Furthermore, sensory stimulation of 
whiskers enhances the expression of BDNF mRNA in the barrel cortex 
(Rocamora et al. 1996; Nanda and Mack, 2000).  
 
There is some evidence that the nuclear transcript may be selectively transported 
to active dendrites and translated locally. Depolarization of hippocampal neurons 
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lead to increased levels of BDNF and TrkB transcripts in dendrites, which may 
allow for increased local protein synthesis (Righi et al., 2000; Tongiorgi et al., 
1997). 
 
Like all neurotrophins, BDNF exerts its biological effects as a homodimer 
(Jungbluth et al., 1994; Kolbeck et al., 1999) and is initially synthesized as pre-
pro-protein both by neuronal and non-neuronal cell types, where the pre-pro-
sequence is presumably cleaved in the endoplasmatic reticulum. Pro-BDNF then 
presumably transits through the Golgi apparatus where it becomes N- 
glycosylated. Because BDNF and neurotrophins in general are normally 
expressed at very low levels, little is known about their processing and secretion 
in vivo.  However, recent studies have suggested that the precursor of NGF is 
released under pathological conditions (Harrington et al., 2004). proNGF may 
induce cell death through p75NTR  in the presence of the type I transmembrane 
protein sortilin to mediate cell apoptosis (Lee et al., 2001; Nykjaer et al., 2001). 
Whether these findings reflect a unique property of proNGF or whether the 
proform of BDNF is similarly active in modulating p75NTR signaling is currently 
unclear. This question was addressed by overexpressing a cleavage-resistant 
mutant form of BDNF. These experiments revealed that proBDNF is an effective 
proapoptotic ligand for cultured sympathetic neurons, also requiring both p75NTR 
and sortilin to initiate cell death (Teng et al., 2005). However, no study has 
demonstrated so far that endogenous proBDNF is released under physiological 
or pathological conditions and that it acts through p75NTR and sortilin to mediate 
cell apoptosis. Very recent work from our laboratory (Matsumoto et al., 2008) 
indicates that proBDNF is rapidly processed intracellularly and that proBDNF is 
not released from neurons (see results 3.7). 
 
Recently, a single nucleotide polymorphism in the bdnf gene leading to a valine 
(Val) to methionine (Met) substitution at codon 66 in the prodomain (BDNFMet) 
was found to be associated in humans heterozygous for the polymorphism with 
memory impairments (Egan et al., 2003). Further, the val66met polymorphism 
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leads to abnormal BDNF trafficking, distribution and activity-dependent release in 
neurons (Chen et al., 2004). A recent study suggests a mechanism for sorting 
BDNF to the regulated secretory pathway in neurons by the binding of its 
prodomain to sortilin, a membrane protein localized to the Golgi apparatus where 
sorting occurs. The study provides evidence that sortilin acts as a sorting 
receptor that preferentially binds proBDNF (val), but binds poorly to 
proBDNF(met) (Chen et al., 2004; Chen et al., 2006).  
 
CNS neurons are thought to release BDNF by activity-regulated secretion 
pathways initiated via the excitatory neurotransmitters glutamate and 
acetylcholine. This process depends on calcium release from intracellular stores 
(Blöchl and Thoenen, 1995, 1996; Canossa et al., 1997; 2002; Griesbeck et al., 
1999). More recently, it has been demonstrated that patterned electrical 
stimulation induces BDNF release in primary sensory neurons (Balkowiec and 
Katz, 2000). Analogous results have been obtained in the central neurons 
(Goodman et al., 1996; Gärtner and Staiger, 2002; Balkowiec and Katz, 2002).  
Additionally, these studies have suggested that BDNF can be released from both 
postsynaptic and presynaptic compartments (Haubensak et al., 1998; Balkowiec 
and Katz, 2002; Hartmann et al., 2001; Kohara et al., 2001). By comparison, little 
is known about potential pathways that downregulate BDNF secretion. So far 
only one study has described negative modulation of BDNF release. Canossa et 
al. (2002) have shown that endogenous production of nitric oxide (NO) 
downregulates BDNF secretion in hippocampal neurons by activating a cyclic 
guanosine monophosphate (cGMP)-dependent signal transduction pathway. 
Activation of this pathway leads to downregulation of Ca2+ release from IP3 
sensitive intracellular stores by protein kinase G.  
 
In general, the detection of  BDNF protein matches the distribution of its mRNA 
(Nawa et al., 1995) and the levels of BDNF protein are known to increase 
postnatally (p1-p21) by about 10-fold in the cerebral cortex and in the 
hippocampus (Kolbeck et al., 1999). However, both in the striatum and the spinal 
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cord substantial levels of BDNF protein were found, while the mRNA studies 
revealed low levels of expression (Hofer et al., 1990; Schmidt-Kastner et al., 
1996; Kolbeck et al., 1999).  
 
The finding that BDNF is expressed in hippocampal neurons and that it is found 
in the cell bodies of cholinergic neurons projecting to the hippocampus that do 
not seem to express BDNF themselves suggest that BDNF is taken up by the 
axon terminals and retrogradely transported back to the cell bodies (Wetmore et 
al., 1991). This postulate was confirmed by DiStefano et al. (1992), who 
demonstrated that 125I-labeled BDNF is retrogradely transported by distinct 
populations of neurons in the central nervous system. In addition, BDNF can 
undergo anterograde transport to presynaptic sites, thus explaining the presence 
of substantial amounts of BDNF in the striatum. In line with this, cortical neurons 
(layer III and V) projecting to the striatum contain high levels of BDNF mRNA 
(Altar et al., 1997). In addition, prevention of axonal transport in striatal afferents 
with colchicine results in elevation of BDNF in the cell bodies of cortical neurons 
and marked decrease in the striatal neuron, a result also observed after unilateral 
lesion of the cerebral cortex (Altar et al., 1997).  
 
1.2.2 BDNF - dendritic growth 
The first identified in vivo function of BDNF during normal development was its 
ability to promote survival of peripheral sensory neurons during programmed cell 
death (Hofer and Barde, 1988). BDNF also regulates dendritic growth of many 
different types of neurons in several different brain regions (Lom and Cohen-Cory, 
1999; Segal et al., 1995; Shimada et al., 1998; McAllister et al., 1999). Exo-
genous BDNF application results in increased dendritic length and complexity of 
pyramidal neurons in the developing visual cortex in a layer specific manner 
(McAllister et al., 1995). The specificity of these effects suggests that BDNF does 
not act simply to enhance neuronal growth but rather acts to modulate particular 
patterns of dendritic arborization. Further, inhibition of spontaneous electrical 
activity, synaptic transmission, or L-type calcium channels, all prevent the large 
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increase in dendritic growth elicited by exogenous BDNF. These results indicate 
that neurons must be active in order to respond to the growth promoting effects 
of BDNF (McAllister et al., 1996). Accordingly, scavenging endogenous BDNF 
causes dendritic retraction, clearly demonstrating that endogenous BDNF 
influences the complexity of dendritic arbors of pyramidal neurons in the 
developing visual cortex (McAllister et al., 1997). Moreover, pyramidal neurons 
transfected to overexpress BDNF retract their existing dendritic spines and 
sprout more dendrites (Horch et al., 1999). Timelapse imaging shows that the 
dendrites of these cells are much more dynamic than non-transfected control 
dendrites, suggesting that BDNF induces structural instability and increases 
plasticity in both dendrites and spines (Horch et al., 1999). However, the 
mechanism by which BDNF exerts its stabilizing effect on dendrite morphology is 
uncertain, not least because some of these studies involved the use of BDNF 
overexpression (see below). BDNF-TrkB signaling might regulate the stability of 
dendrites directly. For example, TrkB signaling might regulate the activity of 
members of the Rho familiy of GTPases, known to modify dendrite number, form, 
and stability in a variety of neuronal types (Threadgill et al., 1997; Li et al., 2000; 
Tashiro et al., 2000; Hayashi et al., 2002; Luo et al., 2002). Alternatively, BDNF 
could influence dendritic structure indirectly through modulating synaptic activity 
(Cline, 2001; Kafitz et al., 1999; Poo, 2001). Regardless of whether BDNF 
directly or indirectly influences dendrite structure, conditional bdnf knockout mice 
(see also introduction 1.3.3) indicate that the essential function of BDNF is 
neither to support neuronal survival nor to regulate initial growth of dendritic trees, 
as suggested by in vitro studies (Gorski et al., 2003, Baquet et al., 2004). Instead 
BDNF appears to support the “survival” of dendritic structure generated through 
BDNF-independent mechanism. These results also suggest a possible role for 
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1.3 Genetically modified mice  
 
Transgenesis and ES cell technologies have opened a unique experimental 
access to the mouse genome and converted this rodent into the most advanced 
model organism for mammalian genetics. Indeed, gene-targeted knockout mice 
represent a powerful experimental system for studying development, behavior 
and physiology. They also may be useful to model certain human genetic 
diseases. The procedure for producing gene-targeted knockout mice involves 
several steps: Exogenous DNA containing a mutant allele of the gene being 
studied is introduced into embryonic stem (ES) cells by transfection. The 
targeting vector recombines with DNA sequences at homologous and in some 
cases at non-homologous sites. The small fraction of cells in which homologous 
recombination takes place can be identified by a combination of positive and 
negative selection: positive selection to identify cells in which any recombination 
occurs and negative selection to remove cells in which recombination takes place 
at non-homologous sites. For this selection scheme to work, the DNA constructs 
introduced into ES cells need to include, in addition to sequences used to 
selectively modifiy the gene of interest, two selectable marker genes. One of 
these additional genes (neor) confers neomycin resitance; it permits positive 
selection of cells in which either homologous (specific) or non homologous 
(random) recombination has occurred. The second selective gene, the thymidine 
kinase gene from herpes simplex virus (tkHSV) confers sensitivity to ganciclovir, a 
cytotoxic nucleotide analog; this gene permits negative selection of ES cells in 
which non-homologous recombination has occurred. Only ES cells that undergo 
homologous recombination can survive this selection scheme. Once ES cells 
heterozygous for a knockout mutation are obtained, they are injected into a 
recipient mouse blastocyst, which subsequently is transferred into a surrogate 
pseudopregnant mouse. If the ES cells are homozygous for a visible marker trait 
(e.g. coat color) then chimeric progeny carrying the knockout mutation can be 
easily identified. These are then mated with mice homozygous for another allele 
of the marker trait to determine if the knockout mutation is incorporated into the 
germ line. Finally, mating mice, each heterozygous for the knockout allele, will 
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produce progeny homozygous for the knockout mutation. Although gene 
targeting by homologous recombination has revolutionized the way gene function 
is assessed in vivo, this strategy has certain limitations. For example, the early 
lethality of some gene disruptions prevents assessment of gene function in the 
adult and aging animal. Moreover, severe developmental defects can 
compromise other systems such as the primary effects of a null mutation are 
difficult to separate from secondary effects. Finally, the normal interactive 
relationships between different factors may be obscured due to the 
compensation of genes not principally affected by this mutation.  
To circumvent these limitations conditional knockout strategies have been 
designed to inactivate genes in a spatiotemporally regulated manner. To obtain a 
tissue-specific gene knockout the Cre/loxP system is most widely utilized, for 
which two different mouse lines have to be separately generated (Sauer et al., 
1998; Nagy, 2000). In one of these two lines a functionally relevant sequence of 
the gene of interest is flanked by two loxP sites using homologous recombination 
techniques in embryonic stem cells. The loxP sites are short sequence elements 
(34 bp) containing two 13-bp inverted repeats flanking an 8-bp asymmetric 
spacer. In the second mouse line, Cre recombinase expression is driven under 
control of defined tissue-specific promotors, which limits the recombination event 
to defined stages of the mouse development and to specific tissues, frequently 
preventing embryonic lethality or developmental adaption. Mating these two 
different mouse lines will yield offspring where Cre recombinase is solely 
expressed in the targeted tissue or cell type in which it will excise the floxed DNA 
fragment. The impact of this approach is reflected by the ever increasing number 
of mouse lines expressing the cre gene under the control of various tissue-
specific promotors or contain a variety of genes equipped with Lox sites for gene 
inactivation or activation (http://www.mshri.on.ca/nagy). Obviously, Cre-induced 
recombination results in irreversible genetic alterations that reflect the activity 
“history” of the promoter driving the cre gene. Thus, this simple approach is 
limited not only by the irreversibility but also by the rigidity of the developmental 
and differentiation program of the organism, which, for example, prevents 
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recombination in a fully differentiated tissue at a later period in the mouse life. 
This difficulty is increasingly often circumvented by using forms of Cre that can 
be activated for example by tamoxifen that can also be administered in specific 
tissues. With regard to BDNF, several approaches with different Cre drivers have 
been used to address the role of BDNF in the mouse nervous system.  
 
1.3.1 Bdnf knockout mice 
Germ-line Bdnf knockout mice are born alive, exhibit reduced growth and die 
before reaching the second postnatal week. They show abnormal behavior 
including circling and spinning movements likely to be caused by defective 
innervation of the vestibular compartments of the inner ear (Jones et al., 1994). 
Ernfors et al. (1994) report neuron loss of more than 80% in the vestibular 
ganglia and that no vestibular axons innervate the sensory epithelium of the 
semicircular canals, saccule, or utricle in postnatal animals. These findings 
suggest that all vestibular ganglion cells innervating inner ear organs associated 
with sensing motion require BDNF for survival. In contrast, the gross appearance 
of structures related to hearing, the cochlea and spiral ganglion was normal. 
Interestingly, if the bdnf gene is replaced by nt3, the severe defects of the 
cochlea innervation and hearing observed in bdnf null mice are rescued, whereas 
the vestibular innervation is not (Agerman et al., 2003). Further analysis of mice 
lacking BDNF indicated a more than 50% loss of neurons in the nodose petrosal 
ganglion complex (NPG), implicating BDNF in the survival of NPGs. The NPG is 
comprised of neurons that relay sensory information critical for the regulation of 
respiration, heart rate and blood pressure. A sub-population of dopaminergic 
NPG neurons that innervate the carotid body are lost in bdnf knockout mice. The 
carotid body is a chemoreceptor organ that senses changes in arterial oxgen and 
carbon dioxide, provides tonic excitatory drive to ventilation, and is the primary 
site that initiates cardiorespiratory reflex responses to hypoxia. Further 
investigations showed that lack of BDNF compromises normal ventilatory 
responses to hypoxia, possibly contributing to premature death in bdnf knockout 
mice (Erickson et al., 1996). Additionally, Carroll et al. (1998) showed that slowly 
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adapting mechanoreceptors of bdnf knockout mice, which are required for tactile 
discrimination, show severely impaired mechanosensitivity and that this defect 
can be rescued by exogenous BDNF. Motor neurons, which were on the basis of 
pharmacological studies predicted to require BDNF, are surprisingly not affected 
in bdnf mutants (Ernfors et al., 1994; Jones et al., 1994), not even in the double 
bdnf/nt4 null mice therefore suggesting that motorneuron survival is not 
controlled by this neurotrophins during normal development (Conover et al., 
1995; Liu et al., 1995).  
Neuronal populations in the CNS reported to be sensitive to BDNF deprivation 
include dopaminergic neurons in the substantia nigra, basal forebrain cholinergic 
neurons, hippocampal neurons, cortical neurons, cerebellar granule cells, and 
retinal ganglion cells (Huang and Reichardt, 2001). However, detailed analysis of 
bdnf knockout mice showed that BDNF does not affect neuronal survival in the 
postnatal brain, but reduces the expression of calbindin, parvalbumin, and 
neuropeptide Y in GABAergic interneurons, implying that BDNF is essential for 
normal differentiation, but not for the survival of most central nervous system 
neurons (Jones et al., 1994). Alternatively, central neurons may have acquired 
functionally compensating signaling pathways that protect them more efficiently 
than peripheral neurons from lack of BDNF (Alcántara et al., 1997; Minichiello et 
al., 1996). Additionally, Cellerino et al. (1997) demonstrated that BDNF plays a 
role in myelination of the CNS, as indicated by hypomyelinated retinal ganglion 
cell axons in mice lacking BDNF (but see below). 
BDNF not only modulates neuronal differentiation in the central nervous system 
but also the number and formation of synapses and the efficacy of synaptic 
transmission. In mice overexpressing BDNF in sympathetic neurons increased 
synapse numbers were observed, whereas a decrease was seen in bdnf 
knockout animals (Causing et al., 1997). Other studies on bdnf knockout mice 
show presynaptic structural defects, including a decrease in the number of 
docked synaptic vesicles and reduced expression of the synaptic vesicle proteins 
synaptophysin and synaptobrevin, indicating impaired presynaptic transmitter 
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release in the absence of BDNF (Pozzo-Miller et al., 1999). Treatment of the 
mutant slices with BDNF reversed these deficits in the hippocampal synapses 
and BDNF appears to regulate high-frequency synaptic transmission by 
facilitating synaptic vesicle mobilization and docking into nerve terminals (Pozzo-
Miller et al., 1999; Kafitz et al., 1999). One of the clearest indications that BDNF 
modulate synaptic transmission comes from the much studied paradigm of long-
term potentiation (LTP). Hippocampal slice preparations from bdnf knockout mice 
exhibited impaired CA1 LTP (Korte et al., 1995). These deficits were reversible 
by either bath application of BDNF or adenovirus-mediated BDNF gene transfer 
(Korte et al., 1995; Patterson et al., 1996; Pozzo-Miller et al., 1999). Additional 
evidence to support the role of BDNF was provided by studies where LTP was 
attenuated if function-blocking BDNF antibodies or BDNF scavenging TrkB-IgG 
proteins are applied on in vitro slices (Chen et al., 1999; Figurov et al., 1996; 
Kang et al., 1997). Besides the immediate actions in the hippocampal 
potentiation, BDNF is essential during the late-phase LTP (L-LTP) that requires 
new protein synthesis (Bradshaw et al., 2003; Kang et al., 1997; Korte et al., 
1998). Mutational analysis of phosphorylation sites of TrkB have demonstrated 
that inhibition of phosphorylation at the PLC-γ-binding site results in reduction in 
LTP in the hippocampus, whereas mutation of the Shc site, essential for 
activation of MAPK and PI3K, does not affect this (Minichello et al., 2002). These 
results were surprising since previous data connects Ras/MAPK pathway to 
synaptic potentiation (English and Sweatt, 1996; English and Sweatt, 1997; 
Patterson et al., 2001; Ying et al., 2002). Still, it is possible that cross-talk 
between TrkB downstream signaling pathways might rescue the Shc-deficit in 
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1.3.2 Bdnf heterozygous mice 
Studies on bdnf heterozygous mice indicated that they are viable and develop a 
phenotype characterized by increased anxiety, aggressiveness and hyperphagia 
accompanied by significant weight gain in early adulthood. Further, these 
mutants have deficits in spatial and contextual learning as well as impaired 
hippocampal LTP that is as affected as in homozygous mutants (Lyons et al., 
1999; Linnarsson et al., 1997; but see Montkowski and Holsboer, 1997; Kernie et 
al., 2000; Liu et al., 2004; Korte et al., 1995; Patterson et al., 1996). Bdnf 
heterozygous mice show also different effects on two forms of cortical LTP: white 
matter-evoked, layer III LTP is normally inducible in bdnf heterozygous mice, 
whereas layer IV-evoked, layer III LTP is impaired. (Bartoletti et al.,2002). 
One consequence of hyperphagia is that bdnf heterozygous mice display 
symptoms reminiscent of human obesity. Their adipocytes are enlarged and they 
have high plasma levels of leptin and insulin. Interestingly, Rios et al. (2001) 
showed that BDNF injection into the ventromedial hypothalamus reduce food 
intake in rats via activation of TrkB receptors and Xu et al. (2003) further 
demonstrated that BDNF is involved in the regulation of food intake as a 
downstream mediator of MC4R signaling. The role of BDNF in the regulation of 
food intake and its relation to MC4R signaling was further investigated by 
Nicholson et al. (2007), who demonstrated an acute hypothalamic release of 
BDNF after local MC4R stimulation with the selective MC4R agonist, MK1. Thus, 
BDNF appears to play an important role as a downstream mediator of the MC4R 
pathway. 
Aggressiveness has been associated with dysfunction of the serotonin system 
(Lyons et al., 1999). At 18 months of age, bdnf heterozygous mice show de-
creased serotonin innervation, as well as decreased levels of 5-HT and              
5-Hydroxyindol acetic acid (5-HIAA) in the hippocampus compared with age-
matched wild-type mice. Further, significant decreases in 5-HT receptor (1A, 1B, 
2A and 2C) mRNA levels in 6-9 months old heterozygous bdnf mice were found 
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in various brain regions (Lyons et al., 1999). To test whether age-accelerated 
loss of serotonergic innervation in bdnf heterozygous mice occurs in other brain 
regions, advances beyond 18 months or is associated with alterations in other 
neurotransmitter systems, Luellen et al., (2007) assessed serotonergic 
innervation in 26-month-old heterozygous bdnf mice. Age-related loss of 
serotonergic axons in the hippocampus was found in heterozygous bdnf mice 
compared with wild-type mice, particularly in CA1 subregion. By contrast, aging 
heterozygous bdnf mice showed increased serotonin innervation of the 
basomedial nucleus of the amygdala. In vivo zero microdialysis experiments in 
heterozygous bdnf mice showed a significant decrease in extracellular serotonin 
levels at 20 months of age. Thus, reduced BDNF seems to be associated with 
altered serotonergic and noradrenergic innervation in aging mice, and in 
particular, with accelerated loss of serotonergic innervation to the hippocampus 
that is manifest as a decrease in basal neurotransmission (Luellen et al., 2007). 
Interestingly, the heightened aggressiveness found in bdnf heterozygous mice 
can be ameliorated by the selective serotonin reuptake inhibitor fluoxetine 
indicating that endogenous BDNF is critical for the normal function of central       
5-HT neurons and for the elaboration of behaviors that depend on these nerve 
cells (Lyons et al., 1999; Kernie et al., 2000). 
1.3.3 Conditional Bdnf knockout mice 
Obesity phenotypes have also been observed in CamKII-BDNF conditional 
knockout mice (CamKII-BDNFKO) that have normal brain content of BDNF during 
perinatal development but a later depletion of BDNF in the postnatal period (Rios 
et al., 2001). These mutants also show hyperactivity and hyperaggression, 
suggesting a serotonin dysregulation. However, the presynaptic serotonin system 
in the adult CamKII-BDNFKO mice appeared normal by histological, biochemical, 
and electrophysiological criteria (Rios et al., 2006). This was surprising as BDNF 
has been reported to support the differentiation of serotonin neurons (Mamounas 
et al., 2000). By contrast, a dramatic postsynaptic 5-HT2A deficit in            
CamKII-BDNFKO mice was found. Electrophysiologically, serotonin neurons 
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appeared near normal, except for an almost complete absence of expected       
5-HT2A-mediated glutamate and GABA postsynaptic potentials normally 
displayed by neurons of the prefrontal cortex and dorsal raphe nucleus. Further 
analysis showed that BDNF mutants had much reduced 5-HT2A receptor protein 
in dorsal raphe nucleus and a similar deficit in prefrontal cortex, a region that 
normally shows a high level of 5-HT2A receptor expression. These findings 
suggest that postnatal levels of BDNF play a relatively limited role in maintaining 
presynaptic aspects of the serotonin system and a much greater role in 
maintaining postsynaptic 5-HT2A receptors (Rios et al., 2006). A significant 
attenuation of 5-HT1A receptor function was also found in the dorsal 
hippocampus of NSE-tTA-TetOp-Cre-BDNF inducible knockout mice (Hensler et 
al., 2007;Monteggia et al., 2004), whereas no difference in 5-HT1A receptor 
function was found in the dorsal or median raphe nuclei or medial prefrontal 
cortex or anterior cingulate cortex, implying that deletion of BDNF expression in 
forebrain regions produces differential effects on distinct 5-HT1A receptor 
populations (Hensler et al., 2007). 
Early-onset forebrain-restricted BDNF conditional knockout mice (Emx-BDNFKO, 
Gorski et al., 2003) that develop in the absence of BDNF in the dorsal cortex, 
hippocampus, and parts of the ventral cortex and amygdala failed to learn the 
Morris Water Maze task, a hippocampal-dependent visuo-spatial learning task. 
Freezing during all phases of cued-contextual fear conditioning, a behavioral task 
designed to study hippocampal-dependent associative learning, was enhanced. 
These mice learned a brightness discrimination task well but were impaired in a 
more difficult pattern discrimination task. Emx-BDNFKO mice did not exhibit 
altered sensory processing and gating, as measured by the acoustic startle 
response or prepulse inhibition of the startle response. Although they were less 
active in an open-field arena, they did not show alterations in anxiety, as 
measured in the elevated-plus maze, black-white chamber or mirrored chamber 
tasks. These data combined indicate that although an absence of forebrain 
BDNF does not disrupt acoustic sensory processing or alter baseline anxiety, 
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specific forms of learning are severely impaired. In addition, Emx1-BDNFKO mice 
displayed a clasping phenotype, similar to that observed in mouse models of 
Huntington`s disease, and developed mild mature-onset obesity. Comparative 
volume measurements of major brain areas indicated that the striatum of 
postnatal Emx-BDNFKO was reduced, explained by shrunken cell somas and 
thinner dendrites of striatal neurons, but not due striatal cell losses. However, 
although no significant striatal neuron losses were detected in young adult Emx-
BDNFKO mice, 35% of striatal neurons were lost in aged Emx-BDNFKO mice. 
These findings indicated that BDNF has no significant survival role in the young 
adult brain, but that it is required for long term survival of neurons. Whether this 
loss of neurons is caused by a direct BDNF trophic survival function only 
apparent with aging, increased susceptibility to excitotoxic injury or some other 
type of insult, remains unclear (Gorski et al., 2003; Baquet et al., 2004).  
 
Nestin-BDNF conditional knockout mice (Nestin-BDNFKO) and CamKII-BDNFKO 
mice with prenatal or postnatal depletion of central BDNF (Chan et al., 2006) 
were dramatically hyperactive during the light/dark cycles and hyperaggressive. 
They also exhibited a depression-like phenotype in the tail suspension test but 
not in the forced swim test. Interestingly, depletion of BDNF from the fetal brain 
had more pronounced effects on aggressive and depressive-like behaviors and 
led to deficits in 5-HT2A receptor content in the medial frontal cortex, highlighting 
the importance of this neurotrophin during development. It seems then that 
BDNF expression both pre- and postnatally is essential for normal modulation of 
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1.4 Aim of the thesis 
To gain further insight into the function of BDNF in the adult brain and to 
complement previous studies by others using Cre lines causing area-specific 
excision of bdnf, we attempted a global BDNF deletion in the CNS by crossing 
floxed bdnf mice with mice expressing Cre from the tau locus. Our results show 
that mice survive several months after birth with nearly undetectable levels of 
BDNF protein in the CNS, which is analyzed in detail in the thesis. These mice 
also provided an essential tool in studies aiming at understanding the 
biosynthesis, storage and release of BDNF in the CNS. 
                                                                                                                   2. Material and Methods 
 
2. Material and Methods 
2.1 Generation of conditional bdnf knockout mice  
The floxed bdnf (fbdnf) mouse line was a kind gift by Drs. Michael Sendtner and Stefan 
Wiese (University of Würzburg, Germany). Briefly, for the generation of mice with floxed 
bdnf alleles, loxP sites were inserted around exon 8, the single coding exon of bdnf. 
Thus, Cre-mediated recombination of floxed bdnf results in a null bdnf allele. Conditional 
bdnf knockout mice lacking BDNF in the entire mouse nervous system (cbdnf ko) were 
generated by breeding mice carrying floxed bdnf alleles with mice expressing Cre from 
the tau locus (Koreths-Smith et al., 2004). Genotypes of mice were determined by PCR 
(see 2.3) using a tail biopsie. Unless specifically mentioned, in all experiments 8 weeks 
old conditional mutants and wild-type littermate controls were used. The control mice for 
all experiments carried floxed bdnf alleles. The mice used in the present study were kept 
on a C57Bl6/Sv129 genetic background. The mice were maintained in the animal facility 
of the Biocenter, University of Basel, Switzerland. 3-4 mice were housed for 2 months 
before the start of experiments under conditions of controlled temperature (21–22 °C) 
and humidity (50%) under a 12:12 h light ⁄ dark cycle (lights on 06.00 h). The mice had 
free access to food and water. All experiments were performed in accordance with the 
Swiss regulations for animal experimentation. 
 
 
2.2 Genotyping of cbdnf knockout mice 
 
Mouse tails were incubated in 500 μl tail buffer (100 mM Trizma hydrochloride, pH 8.5, 
(Sigma, #T-3253); 5mM EDTA (Sigma, #E5134), 200mM NaCl (Fluka #71381), 0.2% 
SDS (Sigma, #L4390) containing 0.1μg/μl Proteinase K (Roche, 10mg/ml stock) on an 
Eppendorf shaker (400 rpm, 55°C over night). The solution was centrifuged (14000 rpm, 
10 min) and the supernatant was transferred into 500 μl isopropanol (Fluka, #91237). 
The solution was centrifuged (14000 rpm, 10 min) and the supernatant was removed 
and precipitated DNA was subsequently dried and resuspended in 35 μl TE (10mM Tris-
HCl, 1mM EDTA, pH 8). DNA was resuspended by agitation at 55°C over night before 
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PCR Master Mix for 50 μl reaction volume: 
 
 
   concentration 
PCR buffer 20 mM Tris-HCl; 50 mM KCl; 50 mM MgCl2 (Sigma, #D1806-250UN) 
dNTPs 200 nM (Sigma, #DNTP100-1KT) 
forward primer 200 nM (Microsynth) 
reverse primer 200 nM (Microsynth) 
Taq Polymerase 2 units (Sigma, #D1806-250UN) 
DNA 1 µl 
 
Primer pair bdnf13 and bdnf14 (for sequence and annealing temperature (AT) see Table 
below) detect the bdnf floxed (800 bp length) and bdnf wild-type allele (600 bp length); 
primer pair bdnf13 and bdnf19 detect the recombinant bdnf allele (1100 bp length). 
Primers tko forward and tko reverse detect the tau wild-type allele (200 bp length) and 
primer pair Cre forward and Cre reverse detect the Cre allele (400 bp length). 
 
 Primer sequence 5` → 3` 
bdnf 13 GTT GCG TAA GCT GTC TGT GCA CTG TGC 
bdnf 14 CAG ACT CAG AGG GCA CTT TGA TGG CTT G 
bdnf 19 CAT GGG CAG TGG AGT GTG AG 
tko forward CTC AGC ATC CCA CCT GTA AC 
tko reverse CCA GTT GTG TAT GTC CAC CC 
Cre forward GCC GAA ATT GCC AGG ATC AG 
Cre reverse AGC CAG CAG CTT GCA TGA TC 
 
PCR amplification protocol for genotyping: 
 
step 1: 95°C 2 min 
step 2: 95°C 30 sec 
step 3: 61°C 30 sec            Step 2-4 were repeated 34 times 
step 4: 72°C 60 sec 
step 5: 72°C 10 min 
 
PCR products and 100 bp ladder (Roche, #11062590001)) were loaded on a 1.8 % 
agarose gel (Sigma #A5093) containing 0.5 μg/ml ethidiumbromide (Applichem,             
#A11520026). Gel detection was performed with Multi Image TM Light Cabinet detection 
system and print outs were done with a Mitsubishi video graphic printer CP770DW. 
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2.3 BDNF ImmunoAssay 
Brains were freshly isolated and subdivided into sub-regions of the brain, weighed, 
collected on dry ice, and stored at -80°C. For the extraction of BDNF, 10 vol/wt of 
extraction buffer [0.05 M sodium acetate, pH 4.0, 1.0 M sodium chloride, 1% (vol/wt) 
BSA, 1% Triton X-100, 0.2 mM phenylmethylsulfonyl fluoride (PMSF), 0.2 mM 
benzethonium chloride, 2 mM benzamidine hydrochloride was added and the tissues 
sonicated to homogeneity. The homogenates were kept on ice for 1 h and the sonication 
repeated three times. The homogenates were centrifuged (15 min, 25000 rpm), the 
supernatants collected and kept over-night at 4°C. A last centrifugation step was 
performed immediately preceding the use of the supernatants. For quantification of 
BDNF from tissue extracts, microtiter plates were coated with mAb#1 (0.4 µg/well) in 200 
µl coating buffer (50 mM NaHCO3, 50 mM Na2CO3, pH 9.7) over night at room 
temperature. Standard amounts of BDNF were diluted in extraction buffer (0.1–3.2 
ng/ml), and 50 µl per well of each concentration was applied to 150 µl incubation buffer 
(0.1 M potassium/sodium phosphate, pH 8.0, 1% BSA, 0.2 mM phenylmethylsulfonyl-
fluoride, 0.2 mM benzethonium chloride, 2 mM benzamidine hydrochloride). Fifty 
microliters per well of the extraction buffer alone was used as negative control. Similarly, 
50 µl per well of the tissue extract supernatants was added to the wells. Subsequently, 
200 µl per well of incubation buffer containing 100 mU/ml mAb#9 POD was applied. 
Plates were incubated for 3 h on a horizontal shaker at room temperature and washed 
with washing buffer (1x PBS, 0.1% Tween (Fluka, #P1379)). Two hundred microliters 
per well of the BM blue POD substrate (Roche, #114 84281001) was incubated for 12 
min at room temperature on a horizontal shaker. The reaction was stopped with 50 µl of 
1 M sulfonic acid (Fluka, #380075) per well, and the intensity of the reaction product was 
measured in a microplate reader (Biotek, PowerWave XS, KC4 software) at 450/650 nm. 
A standard curve was generated from the BDNF standard wells on each plate. BDNF 
levels in tissue extracts were determined by comparison with the standard curve using 
the GraphPad Prism software. All samples from an individual animal were run in 
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2.4 Tail suspension test 
Wild-type and cbdnf knock-out mice at various ages were analyzed for limb clasping by 
suspending them from their tails at least 1 foot above a surface for 1 min. A clasping 
event was defined by the retraction of either or both hindlimbs into the body and toward 
the midline. Mice were scored on a simple “yes” or “no” basis. 
 
2.5 Body Weight 
Wild-type, heterozygous and mutant mice were maintained in a 12-h light/12-h dark 
cycle and fed a standard chow diet and water ad libitum. Growth curves for males and 
females were obtained by measuring body weight at 4, 6, 8, 10, 12 wk of age. Statistical 
significance was determined using a paired t-test and all values represent mean ± SEM. 
 
2.6 Measurement of Locomotor Activity 
 
Differences in locomotor activity were assessed during the light cycle by placing mutants 
2 months of age and age-matched controls individually into cages and monitoring 
locomotor activity at baseline and after exposure to a novel chamber. Baseline activity 
was measured for 1 h subsequent to allowing animals to habituate to the activity monitor 
for 3 h. Activity was also monitored for 1 h (habituation period) immediately after 
placement into a fresh cage and for 1 h subsequent to habituation. Exposure to a novel 
cage has been used previously as a mild stressor (Baumgartner et al., 2001). Total 
activity was quantified using the Opto-Varimex-Mini infrared photocell activity monitor 
(Columbus Instruments, Columbus, OH). Statistical significance was determined using a 
unpaired t- test and values represent mean ± SEM. 
 
2.7 Light/Dark Exploration Test 
The light/dark exploration test is an accepted and frequently used anxiety test (van 
Gaalen et al., 2000). To test anxiety behavior, control and BDNF conditional mutant mice 
(n = 4), 4–8 wk of age, were placed in a box (20x20x45 cm) containing a light and dark 
chamber. The light chamber constructed of clear plastic material was two-thirds the size 
of the box and was brightly illuminated by a 150-W lamp. The dark compartment 
occupied the remaining third part of the box and was constructed of black plastic 
material that prevented the entrance of light. The two chambers were separated by a 
black plastic wall with a doorway (7x7 cm) to allow passage from one chamber to the 
other. Animals were placed in the dark compartment, and the latency for the first 
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transition to the light compartment, total time spent in the light compartment, and 
numbers of transitions from the dark compartment to the light compartment were 
monitored for a period of 5 min. The box was cleaned after testing each animal. 
Statistical significance was determined using an unpaired t-test and values represent 
mean ± SEM. 
 
2.8 Volumetric analyses 
Animals were heavily sedated by intraperitoneal injection of Ketalar (Parke Davies, 
5mg/kg)/Rompun (Bayer Health Care, 100mg/kg) and perfused transcardially with 4% 
paraformaldehyde (Sigma, #P6148) in 1x PBS. The brains were removed and kept in 
fixative over night. Serial coronal 30-35 µm thick sections were obtained with a 
vibratome (Leica, VT 1000 S). Consecutive sections were submitted to cresyl-violet 
staining (Fluka, #255246). Stained sections were dehydrated in graded ethanol (Fluka, 
#459836) and xylene (Fluka, #95680), and coverslipped using Eukitt (Kindler, Freiburg, 
Germany). Sections were examined with a light microscope (Leica, 6x Ojective). Strict 
morphological criteria were used consistently in all mice to determine the boundaries of 
striatum, hippocampus and cortex (George Paxinos, The mouse bain). Briefly, the 
superior boundary of the striatum was defined by the corpus callosum, the lateral 
boundary by the external capsule, and the medial boundary by the lateral ventricle and 
the corpus callosum. The ventral boundary of the striatum was delineated by the anterior 
commissure, excluding the nucleus accumbens. For the cortex, the primary ventral 
boundary was the corpus callosum. A line connecting the rhinal fissure to the corpus 
callosum was used in more medial sections to define the anterior ventral portion of the 
neocortex. Entorhinal cortex was also included in cortical volume measurements. 
Hippocampal outlines encompassed the dentate gyrus, the CA1–3 fields of Ammon’s 
horn, the subiculum, the presibiculum and the fimbria of the hippocampus. Starting with 
one of the four most anterior sections, selected on a random basis across brains, every 
fourth section through the anterior-posterior extent of both hemispheres of the brain was 
analyzed. Using this sampling strategy, 15 histological sections per brain were analyzed.  
All volumetric quantifications were performed with a Leica microscope (6x Objective) 
equipped with a camera. When calculating the volume of striatum, hippocampus, and 
cortex, the boundaries were defined and the volumes were determined with AnalysisD 
software according to the Cavalieri principle (Regeur and Pakkenberg, 1989). 
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2.9 Neuron/oligodendrocyte quantification 
Mice were killed by cervical dislocation and the brains were extracted and embedded in 
O. C. T. medium (Electron Microscopy Sciences, #62550-01), and stored at -80°C. 
Serial coronal sections (10 µm) were obtained from cbdnf knockout and wild-type mice 
using a cryostat (Leica, CM 30505), and anti-NeuN/anti-Olig2 (Chemicon, MAB377, 
AB9600) immunhistochemistry was performed to identify neurons and oligodendrocytes. 
Briefly, after quenching of endogenous peroxidase activity with 0.3% H2O2/MeOH 
(Sigma, #32338-1) for 30 min, sections were blocked and permeabilized in 5% normal 
goat serum (Sigma, #G9023) and 0.5% NP-40 (Sigma, #74385) in 1x PBS for 1 hr. 
Sections were then washed and incubated overnight at 4°C with an antibody against 
NeuN (1:500)/Olig2 (1:500), followed by incubation with a secondary antibody, 
amplification using the Vectastain Elite ABC kit (Vector Laboratories, PK-6101, PK-6102), 
and incubation with AEC substrate (Vector Laboratories, SK-4200). To compare the 
number of neurons in the striatum of cbdnf mutants and wild-type mice, the number of 
NeuN-immunoreative cell bodies was counted in 8 (10 µm thick) sections containing the 
striatum and 120 µM apart using a 40x objective. NeuN positive cells were visualized 
using a Leica microscope equipped with a camera. Cell body counts in the acquired 
image were conducted using the measuring module of the AnalysisD software program. 
Statistical significance was determined using an unpaired t-test and all values represent 
mean ± S.E.M. 
 
2.10 Electron microscopy  
For electron microscopic analysis, mice were deeply anesthetized with Ketalar (Parke 
Davies, 5mg/kg) and Rompun (Bayer Health Care, 100mg/kg) and fixed by transcardiac 
perfusion with 3% glutaraldehyde/3% formaldehyde (Server, #23115; Sigma,#F-1635) in 
0.1 M cacodylate buffer (0.2M Na(CH3)2 AsO2 • 3H2O, pH 7.4). Corpus callosum, 
spinal cord (L3-6) and optic nerve from 2 months old wild-type and cbdnf ko mice were 
dissected and kept over night for postfixation in 3% glutaraldehyde/3% formaldehyde in 
0.1M cacodylate buffer at 4°C. Tissue sections were extensively washed with washing 
buffer (0.5% sodium chloride, 0.1M cacodylat buffer, pH 7.2) and then postfixed in 1% 
osmium tetroxide/1.5% potassium hexanoferrate (Sigma, #75632; Fluka, #480010) 
rinsed in 0.1 M cacodylate buffer for 3 h. Afterwards corpus callosum, spinal cord and 
optic nerve were dehydrated through graded ethanol solutions (70%, 80%, 96% and 
100%), and soaked in propylene oxide (Fluka, #82320) for 1h. After infiltration for 2 h in 
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propylene oxide and Epon (Fluka, #45345) 1:1, samples were polymerized in propylene 
oxide and Epon 3:1 at room temperature overnight. Samples were then embedded with 
plastic capsules (Electron Microscopy Sciences, #70905-12) and polymerized at 37°C 
for 2h, followed by 45°C for 24h. Finally, the samples were polymerized at 65°C for 3 
days. Semi-thin sections (1 µm) were cut in a plane orthogonal to the longitudinal axis of 
the optic nerve, spinal cord, corpus callosum with an ultramicrotome (Reichardt-Jung) 
and were stained with toluidine blue for light microscopy (DMRE Leica). Selected areas 
were further sectioned at 0.6 µm (ultrathin sections) for transmission electron 
microscopy. Ultrathin sections were collected on 200-mesh grids (Sigma, #G5901) and 
stained with lead citrate (Reynolds 1963). Immediately after staining, the grids were 
thoroughly washed with water. After removing the remaining water with filter paper 
(Schleicher & Schüll), the grids were air-dried before examination. Ultrathin sections 
were examined with an electron microscope (Philips EM400) at an accelerating voltage 
of 80 kV. Electron micrographs were randomly taken from the optic nerve, spinal cord 
and corpus callosum without knowing the genotype of the mice. The total area of the 
optic nerve and spinal cord was measured from semi-thin sections stained with toluidin 
blue using Analysis D software. Counts of axons were made at a final magnification of 
8600x (optic nerve), 1600x (spinal cord) and 6500x (corpus callosum). For each probe, 
the sample consisted of 15 pictures corresponding to a total area of 18.33 μm2 (optic 
nerve), 315 μm2 (spinal cord), 18.35 μm2 (corpus callosum). The axon size and thickness 
of myelin sheaths were measured by using Analysis D software at a final magnification 
of 8600x (optic nerve), 1600x (spinal cord) and 6500x (corpus callosum). Statistical 
analysis was performed with Microsoft Excel (t-test); all the graphs were generated in 
GraphPad Prism 4, with the exception of axonal size distribution, which was generated 
in Exel. 
 
2.11 Quantitative RT-PCR  
Total RNA was isolated by Trizol extraction (Invitrogen) from brains of 8 week old cbdnf 
ko and wild-type mice. 5 µg of RNA from each sample was used to generate cDNA, by 
using the SuperScriptTM First-Strand Synthesis System for RT-PCR kit (Invitrogen). 
Two microliter of the total RT product was used for each PCR reaction. Dye (Metabion) 
and HotStar Taq (Qiagen, #203203) were included in the PCR mix. Primers were as 
follows: MAG, sense 5`-CGCACGGTGGAGCTGAGT- 3`, antisense 5`-CCA CCA CCG 
TCC CAT TCA-3`, probe 5`-Fam-TCA TGT ATG CAC CTT GGA AGC CC-Tamra-3`; 
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MOG, sense 5`TGG CCC AGC TGC TTC CT- 3`, antisense 5`-GGA TGG GAT ACC 
CTG GTC CTA-3`, probe, 5`-Fam-TCA CTC TGA ATTGTC CTG CAT AGC-Tamra-3`, 
PLP, sense 5`-AGC GGG TGT GTC ATT GTT TG – 3`, antisense 5`-ACA ACA GTC 
AGG GCA TAG GTG AT – 3`, probe, 5`Fam –AAA CTT GTC GGG ATG TCC TAG 
CCA-Tamra-3`,  MBP, sense 5`-GAC CCA AGA TGA AAA CCC AGT AGT-3`, antisense 
5`-TTG GGA TGG AGG TGG TGT TC - 3, probe 5`-Fam-CAT TTC TTC AAG AAC ATT 
GTG ACA CCT – Tamra-3`, CNPase, sense 5`-TGT GCT GCA CTG TAC AAC CAA AT-
3`, antisense 5`-AGG CCT TGC CAT ACG ATC TCT-3`, probe, 5`-CAC CAC CTC CTG 
CTG GGC GTA TTC T-Tamra-3`, OSP, sense 5`ACT GGT CTC TAC CAC TGC AAA 
CC-3`, antisense 5`-AGC AAT CAT GAG GGC TCT ACA AG-3`, probe 5`-Fam-CAT 
CCT CAT CCT TCC AGG CTA CGT-Tamra-3`, MOBP, sense 5`-CTG CTG CCC ACC 
CTT CAC-3`, antisense 5`-CGC TCT TGC AGA TGC TGT ACT T-3`, probe, 5`-Fam-
CAA CTC CAA GCG TGA GAT CGT GGA CC-Tamra-3`, NGF, sense, 5`-GCC AAG 
GAC GCA GCT TTC TAT – 3`, antisense, 5`-AGT GAT CAG AGT GTA GAA CAA CAT 
GGA – 3`, probe, 5`-FAM-CTG GCC GCA GTG AGG TGC ATA GC – Tamra-3`; NT-3 
(Mm_00435413_s1, Applied Biosystems); NT4/5 (Mm_01701592_g1; Applied Bio-
systems); GAPDH (Mm_99999915_g1; Applied Biosystems). Triplicate reactions were 
run for each sample for all myelin proteins, neurotrophins and GAPDH. Reactions were 
run on the ABI PRISM 7000 Sequence Detection System (Applied Biosystems). 
Threshold cycle for each reaction was determined, using the ABI Prism 7000 SDS 
software (Applied Biosystems). The expression levels of myelin and neurotrophin genes 
were normalized against GAPDH. 
 
2.12 Biosynthesis and processing of endogenous BDNF in hippocampal   
        neurons that store and secrete BDNF, but not proBDNF 
 
2.12.1 Generation of bdnf-myc knock-in mice 
 
bdnf-myc knock-in (bdnf-myc) mice were generated by substituting exon V of the bdnf 
gene with a human c-myc tagged version of the gene. c-Myc was added at the C-
terminus of wild-type BDNF following deletion of the last 3 amino acids. Recombinant 
BDNF-myc protein is indistinguishable from wt BDNF in survival assays using cultured 
chick nodose neurons and TrkB phosphorylation assay with mouse cortical neurons. 
Over several generations, the behavior and phenotype of bdnf-myc mice were 
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indistinguishable from those of wild-type animals and the levels of BDNF-myc protein 




Recombinant cleavage-resistant pro-BDNF (3 arginine residues (R-4, R-3, and R-1 of 
the pro-domain), a site prohormone convertases recognize, were replaced with alanine) 
and BDNF-myc were produced using COS7 cells as in Fayard et al., 2005. Recombinant 
purified BDNF was a kind gift of Regeneron Pharmaceuticals (NY). Recombinant purified 
nonglycosylated pro-BDNF and polyclonal anti-pro-BDNF antibodies were a kind gift of 
Alomone Labs Ltd. (Israel). Monoclonal anti-BDNF antibodies (mAb#9 and mAb#1) were 
in Kolbeck et al., 1999. Polyclonal anti-BDNF (pAbN20) and anti-Myc antibodies (A14G) 
were purchased from Santa Cruz Biotechnology, Inc. (CA). 
 
2.12.3 Extraction of BDNF from mouse hippocampus 
 
BDNF extraction was performed as described in Kolbeck et al., 1999, with the following 
modifications. Hippocampi were dissected from 7-8-week old wt, bdnf-myc, and cbdnf 
KO mice, weighed, and then stored at –80°C. Five vol/wt of extraction buffer containing 
0.05 M CH3COONa (pH4.0), 1 M NaCl, 0.1% Triton X-100 was added. For 
immunoprecipitation, twenty five vol/wt of RIPA buffer (50mM Tris-HCl (pH7.4), 150 mM 
NaCl, 1 mM EDTA, 1% Triton-X 100, 1% Na deoxycholate, and 1% SDS) was added. To 
prevent protein degradation, especially pro-BDNF cleavage during extraction, freshly 
prepared protease inhibitors including protease inhibitor cocktail (Roche, Switzerland), 
10 μM 1, 10-phenanthroline monohydrate, and 10 mM 6-aminohexanoic acid, 10 μg/ml 
aprotinin were added to the buffer. The tissues were sonicated, and the homogenates 
were centrifuged, followed by collection of the supernatants as in Kolbeck et al., 1999.. 
 
2.12.4 Cell culture 
  
Cultured hippocampal neurons were prepared from embryonic day 16 mice (RCC, 
Switzerland). The dissected hippocampi were digested with trypsin and dissociated 
mechanically. Cells were plated in poly-D-lysine-coated dishes at 2x105 cells/cm2 of cell 
density. One day after plating, serum (10% fetal calf serum)-containing medium was 
replaced with complete medium (Bibel et al., 2004). The cultures were then maintained 
until performing experiments. 
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COS7 cells were transfected with constructs encoding rat wt bdnf or myctagged version 
of bdnf (bdnf-myc) as in Fayard et al., 2005. Constructs encoding bdnf-myc were a kind 
gift of Dr. Berengere Fayard (FMI, Basel, Switzerland), whereby human c-Myc was 
added at the end of C-terminus of wild-type BDNF, following deletion of the last 3 amino 
acids. 
 
2.12.6 Pulse-chase experiments 
 
COS7 cells or cultured hippocampal neurons were then preincubated with 
methionine/cysteine (Met/Cys)-free media for 2 hours, metabolically labeled for 2 hours 
with 200 mCi/ml of [35S]Met/Cys labeling mix (Amersham Pharmacia Biotech, IL), and 
rinsed with PBS. Cultures were incubated with fresh media and chased for indicated 
time. Cell lysates with RIPA buffer and conditioned media were then collected, followed 
by immunoprecipitation with indicated antibodies. After sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE), gels were fixed in 30% methanol and 
10% acetic acid. Radioactive signals were detected with Photoimager (STORM 840; 
Amersham Pharmacia Biotech). 
 
2.12.7 Western blotting 
 
20 μg of total proteins in tissue lysates were separated on electrophoresis using 4-12% 
gradient SDS-polyacrylamide gels. After transfer of the proteins on the membrane, the 
membranes were blocked with 0.1% Tween 20/phosphate buffered saline (PBST) 
containing 5% skim milk, followed by incubating with polyclonal anti-BDNF, anti-pro-
BDNF or anti-Myc antibody (1:500 with PBST containing 2% skim milk) at 4°C overnight. 
After 1-hour incubation with horseradish peroxidase-conjugated mouse anti-rabbit IgG 
antibody at room temperature, the signals were visualized using an ECL 
chemoluminescence system (Amersham Bioscience. NJ). Western blots following 
immunoprecipitation of tissue lysates (500 μg of total proteins) were performed using IP-
Western Kit (GenScript) to eliminate non-specific signals from protein G (a protein with a 
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2.12.8 Electrophysiological experiments 
 
Hippocampal transverse slices (400 μm thick) were prepared and maintained using 
standard procedure using a Vibratome (Leica VT 1000S, Wetzlar, Germany). Artificial 
cerebrospinal fluid (ACSF) at 4°C, containing (in mM) 124.05 NaCl, 2.95 KCl, 1.25 
KH2PO4, 4.07 MgSO4, 1.87 MgSO4·7 H2O, 25.95 NaHCO3, 2.5 CaCl2·2 H2O and 9.98 
glucose was used. All slices were prepared from 2-3-week old mice. For all experiments 
only littermates were used. All experiments were performed and analyzed without the 
experimenter knowing the genotype of the preparation. Monopolar tungsten electrodes 
were used for stimulation in the CA3 Schaffer-collateral region. Synaptic field potentials 
were elicited with frequency of 0.1 Hz. Responses were recorded with glass 
microelectrodes filled with 3 M NaCl (8-16 MOhm), and placed in the apical dendritic 
region (stratum radiatum) of the CA1 pyramidal neurons. LTD was induced with a low-
frequency-stimulus (LFS) of 1Hz for 15 min (900 pulses). LTP was induced in the same 
slice that was used for the LTD experiments. For LTP induction three consecutive theta 
burst stimuli (TBS) were used. The TBS was delivered with 10 bursts of 4 pulses each 
(100 Hz, 200 μs duration, 200 ms inter-bust interval, 10 s inter-stimulus-interval [ISI]). As 
an indicator of synaptic strength the initial slope of the evoked fEPSPs was calculated, 
averaged across six consecutive measurements and expressed as percentages relative 
to the baseline mean. The normalized data of each experiment were then time-matched, 
averaged across experiments and expressed as means (±SEM). All statistical tests were 
unpaired t-test, two-tailed. 
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3.1  Generation of conditional bdnf (cbdnf) knockout mice 
A floxed bdnf transgenic mouse line (a generous gift from Drs. Michael Sendtner 
and Stefan Wiese) was crossed with a mouse line expressing Cre from the tau 
locus (Korets-Smith et al., 2004; fbdnfxtau::Cre; Fig. 1a). Tau, a microtubule 
associated protein, is expressed in the vast majority, if not in all, post-mitotic 
neurons (E10.5) of the central and peripheral nervous system. Mice thus 
resulting from this breeding scheme (Fig. 1b; bdnf Δ/Δ tauCre/wt ; cbdnf ko;) should 
develop in the absence of detectable BDNF in the central and peripheral nervous 
system assuming that Tau-expressing cells are the major sites of BDNF 
expression. A previous study revealed that, intercrosses between the tau::Cre 
mouse line and Cre-activatable reporter lines resulted in offsprings with 
recombination either restricted to the nervous system or throughout the entire 
embryo, indicating that Tau is expressed very early in development and that it is 
the context in which the loxP target alleles are expressed that contributes to 





Fig. 1: Generating adult mice lacking BDNF in the CNS. a: A, Diagram of the bdnf  lox allele. Exon VIII, the BDNF coding 
exon, is shown schematically flanked by lox sites (filled triangles).B, Targeted insertion of the Cre recombinase into the 
tau locus. Structure of the targeted allele; the Cre coding segment inserted into exon 1 provides the translation start site 
(ATG). C, Diagram of the bdnf lox allele after Cre-mediated recombination. BDNF-coding sequences in exon VIII are 
excised. b: Breeding scheme. Mice homozygous for the floxed bdnf allele are mated with mice homozygous for the 
tau::Cre allele to obtain mice heterozygous for both the floxed bdnf allele and tau::Cre allele (F2). The double 
heterozygous mice are mated with mice homozygous for the floxed bdnf allele to obtain fbdnfxtau::Cre mutants (F3). Δ: 
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As determined by PCR using genomic DNA prepared from the progeny of fbdnfx 
tau::Cre (Fig. 2), the fbdnfxtau::Cre mutants fell into 3 categories: bdnf full 
knockout (19%), bdnf mosaic (5%) and tissue-specific bdnf knockout mice (1%) 
(Fig. 3A). Bdnf full knockout mice carried a bdnf null and no floxed bdnf allele, 
indicating that the levels of Cre present in the zygote is sufficient in many cases 
to catalyze excision of the floxed allele. Bdnf mosaic mice showed a floxed and a 
bdnf null allele, presumably as the result of a stochastic excision of the floxed 
bdnf allele in the preimplantation or early postimplantation embryo. Tissue- 
specific conditional bdnf knockout mice had a floxed bdnf allele and no bdnf null 
allele, indicating that Cre-mediated recombination did not take place in tissues 






Fig. 2: Genotyping fbdnfxtau::Cre littermates. The genotype of each animal is assessed by PCR of genomic DNA isolated 
from tail (see Material and Methods for primer sequences and protocol). Primers for bdnf gene detection amplify a wild-
type (bdnf +/+) fragment of 600 bp length and a floxed (bdnf flox/flox) fragment of 800 bp length. Primers for Cre gene 
amplify a fragment of 400 bp length. Primers for bdnf null gene detection amplify a fragment of 1150 bp length. Lane 1: 
bdnf full knockout mouse; Lane 2: tissue-specific bdnf knockout mouse; Lane 3: bdnf mosaic knockout mouse; Lane 4: 
heterozgous tissue-specific bdnf knockout mouse; Lane 5: heterozygous bdnf mosaic knockout mouse; Lane 6: bdnf wild-





























Fig. 3: Results of genotyping fbdnf xtau::Cre littermates. A) Total number of fbdnf xtau::Cre littermates (SV129/ C57/Bl6; 
2186 mice) analyzed by PCR. B) Total number of analyzed fbdnf xtau::Cre littermates in C57/Bl6 backround (200 mice). 
As Korets-Smith et al. (2004) demonstrated that the percentage of tissue-specific deletion of the tau::Cre deleter was 
dependent on the Cre reporter used, we backcrossed the floxed bdnf as well as the tau::Cre mouse line, both 
Sv129/C57/Bl6, into a C57/Bl6 backround. To this end, the floxed bdnf mouse line was backcrossed 8 generations (~99% 
C57/Bl6), the tau::Cre mouse line 5 generations (94% C57/Bl6). As it turned out, all mutants generated in the C57/Bl6 
backround were bdnf full knockout mice. Yellow: bdnf heterozygous and wild-type mice; red: bdnf full knockout mice; blue: 
mosaic bdnf knockout mice; turquoise: tissue-specific bdnf knockout mice. 
 
We found the bdnf mosaics and tissue-specific bdnf knockout mice were able to 
survive up to eight months. To confirm that BDNF was depleted from their CNS, 
BDNF protein levels were measured by ELISA. A ≥ 95% reduction was found 
throughout the CNS, compared with wild-type mice (unpaired t-test, p<0.001, Fig. 
4). Beside the CNS, BDNF is known to be also expressed in peripheral tissues 
such as heart, lung and muscle (Maissonpierre et al., 1990). Previous studies 
have also indicated that in the absence of BDNF, sensory axons fail to innervate 
the carotid body, contributing to the early death of bdnf full knockout mice 
(Hellard et al., 2004, Erickson et al., 1996). In our mosaic animals, BDNF protein 
levels were found to be unchanged in heart, lung and skeletal muscle (Fig. 5). 
Based on these findings, we assume that organs critical for postnatal survival 
such as the carotid body are likely to be innervated, such that vital functions, 
including breathing, develop adequately. It thus appears that bdnf mosaic and 
tissue-specific bdnf knockout mice (summarized as cbdnf ko) represent an 
interesting and novel model to study the role of BDNF in the adult mouse 
nervous system. As the postnatal increase in BDNF levels is completed by about 
3 weeks after birth, we focused our analysis of cbdnf ko mutants at 8 weeks after 
birth when mice can be considered as sexually mature, young adult animals. 
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Fig. 4: Quantification of BDNF protein by ELISA at P56 in various CNS areas. All results are presented as a mean 



























Fig. 5: Quantification of BDNF protein by ELISA at P56 in peripheral tissues. All results are presented as a mean 
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3.2  Phenotype of cbdnf knockout mice 
 
3.2.1 General observations 
At birth, cbdnf ko mice had the same size as their littermates, respond to a foot 
pinch, and display motor activity. After birth, conditional mutants lag behind 
littermates in growth, display periods of hyperactivity and of inactivity and can 
easily be recognized by their posture and movement. However, there was no 
significant difference in body length between 8 weeks old cbdnf ko and wild-type 





Fig. 6: Normal skeletal growth of 2 months old cbdnf ko mice. No significant differences in body length were detected 
between the genotypes. Results are presented as a mean ±SEM determined from the analysis of 6 mice per genotype   
(p>0.05; unpaired t-test). Black bars are cbdnf ko and white wild-type mice. 
 
 
In their home cage environment, 8 weeks old cbdnf ko mice displayed no obvious 
movement abnormalities such as rotation, or alteration of stereotyped behaviours 
that would distinguish them from controls. However, typical movements 
associated with exploratory behaviours such as brief stopping, sniffing, rearing, 
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3.2.2 Body weight of cbdnf ko mice 
Beyond 4 weeks of age, female conditional mutants had increased body weights 
compared with littermate controls, and this difference reached statistical 
significance at 6 weeks of age (43% increase in body mass compared with wild-
type, (p<0.05, n=3; Fig. 7A). By 12 weeks of age, mutant females were 72% 
heavier than age-matched controls, respectively. The weight of mutant females 
at 12 weeks was 38.5g ±2.12 compared with 22.3g ±2.21 for the controls 
(unpaired t-test; P=0.003, n=3/genotype; Fig. 7A). Surprisingly, male cbdnf ko 
mice did not become obese. This is in contrast with previous reports on the 
phenotype of heterozygotes (Lyons et al., 1999; Kernie et al., 2000). Conditional 
mutant males had a mean weight value of 29.26g ±2.69 compared with 27.02g   
±1.31 for the controls by 6 weeks of age (unpaired t-test; P>0.05, n=6 mice per 
genotype; Fig. 7B).  We have no explanation for this surprising sex-specificity of 
the matured obesity phenotype (only observed in female animals), an obser-
vation that warrants further studies. 
 
Fig. 7: Body weight and skeletal growth of cbdnf ko mice.  
A) Growth of female cbdnf ko and control mice. Female cbdnf ko mice 
show maturity-onset obesity. B) Growth of male cbdnf ko and control 
mice. Male cbdnf ko mice show no maturity-onset obesity. All results 
are presented as a mean determined from the analysis of n             
mice/genotype (*, p<0.05, unpaired t-test). Black bars are cbdnf ko and 
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3.2.3 Activity of cbdnf ko mice 
cbdnf ko mice showed overall normal locomotor activity. However, they were 
hyperactive for brief periods of time when exposed to a novel environment.  
 
3.2.4 Anxiety-like behavior of cbdnf ko mice 
cbdnf ko mice showed an increase in anxiety-like behavior during the light/dark 
exploration test (Fig. 9). At all ages examined it took mutants longer to make the 
first transition from the dark to the light compartment, and they spent less time in 





Fig. 9: Dark/light exploration test. Each cbdnf ko and control mouse was tested for a period of 5 minutes in a 2-chamber 
(dark v. light) test. A: 4 weeks old mice, B: 6 weeks old mice, C: 8 weeks old mice. All results are presented as a mean 
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3.2.5 Brain weight of cbdnf ko mice 
At 8 weeks, the brain weight of cbdnf ko mice was significantly reduced (0.37mg 
±0.02) compared with that of wild-type mice (0.44mg ±0.01) (unpaired t-test,    
p<0.05; Fig. 10a) In addition, cbdnf ko mice exhibit an early onset clasping 
phenotype that is seen in several neurodegenerative mouse models including in 
particular Huntington`s disease (Lalonde, 1987; van den Akker et al., 1999; 
Auerbach et al., 2001; Guidetti et al., 2001; van Dellen et al., 2001). This 

































Fig. 10: cbdnf ko mice have reduced brain weight and show clasping phenotype. a: Brain wet weight of cbdnf ko mice was 
significantly different from control. Results are presented as a mean ±SEM determined from the analysis of n 
mice/genotype (*p<0.05; unpaired t-test). Black bars are cbdnf ko and white wild-type. b: Clasping phenotype. cbdnf ko 
and wild-type mice at 4, 6 and 8 weeks were suspended by their tails for 1 min. Clasping was defined as the balling up of 
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3.3  Comparative CNS volume measurements of major brain areas in cbdnf    
knockout mice  
 
To determine if there is a global or an area-specific reduction in brain size of 
cbdnf ko mice, comparative volume measurements were performed at P14, P35, 
and P56 on Nissl-stained sections of the hippocampus, cerebral cortex and 
striatum. The hippocampal volume of cbdnf ko mice was not significantly reduced 
compared with wild-type controls at all ages examined (Fig. 11), though a small  
(~10%) but not statistically significant reduction was observed at P14. At P35 and 
P56, average hippocampal volumes of cbdnf ko mice were comparable to wild-
type values (unpaired t-test, p>0.05, Fig. 11). In contrast to the hippocampus, the 
volume of the cerebral cortex of cbdnf ko mice was smaller than controls at all 
ages examined (Fig. 11). At P14, a statistically significant 17% reduction was 
observed between cbdnf ko mice and wild-type controls (unpaired t-test, p<0.05, 
Fig. 11). At P35 and P56, the cortex of cbdnf ko mice was ~ 20% smaller than 
the cortical volumes of wild-types (unpaired t-test, p<0.05). Striatal volume was 
reduced in cbdnf ko mice compared with wild-type at all ages analyzed (Fig. 11). 
At P14 and P35, the striatal volume of cbdnf ko mice was ~16% less than wild-
type littermates (unpaired t-test, p<0.05). At P56 the difference in striatal volumes 
between mutant and wild-type mice reached 36% and was significantly reduced 





Fig. 11: The volume of both, the striatum and cortex, but not of the hippocampus fails to grow in the mutant between P14 
and P56. Measurements were performed on Nissl stained sections from cbdnf ko and wild-type mice (P14; P35; P56) by 
Cavalieri analysis. All results are presented as a mean ±SEM determined from the analysis of n mice/genotype (*p< 0.05; 
unpaired t-test). Black bars are cbdnf ko and white wild-type.  
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Comparative volume measurements were also performed on Nissl-stained 
sections on the dentate gyrus and the olfactory bulb, as these brain areas are 
well-known sites involved in adult neurogenesis and BDNF has been repeatedly 
discussed in the context of adult neurogenesis (see discussion). However, 
neither the volume of the dentate gyrus nor that of the olfactory bulb of cbdnf ko 
mice were significantly reduced compared with wild-type controls at P56 (Fig. 12). 
While these results may suggest that endogenous BDNF does not play a 
significant role in adult neurogenesis, a recent report indicates that only a small 
portion of newly generated neurons stably integrate in the dentate gyrus 
(Ninkovic et al., 2007)  
 
In sum then, comparative volume measurements of major brain areas in 8 weeks 
old cbdnf ko mice showed a region-specific volume reduction of the cortex (20%) 
and striatum (36%), but not in the hippocampus. Therefore, the loss of brain 
volume associated with an almost complete absence of BDNF in the CNS 
reveals a surprising regional specificity in the postnatal growth-promoting effects 


























Fig. 12: Comparative volume measurements in the dentate gyrus and olfactory bulb at P56. Measurements were 
performed on Nissl stained sections of cbdnf ko and wild-type mice by Cavalieri analysis. All results are presented as a 
mean ±SEM determined from the analysis of n mice/genotype (*p<0.05; unpaired t-test). Black bars are cbdnf ko and 
white wild-type.  
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3.4  The striatal volume is reduced at 8 weeks, but cell losses are not 
apparent 
 
To examine whether the decrease in striatal volume was caused by cell loss, 
neuronal numbers were determined using NeuN staining. No significant 
differences were found (unpaired t-test, p>0.05, Fig. 13 D), though neuronal 
density was increased (as expected) (p<0.05, Fig. 13 A, C). To determine 
whether the number of mature oligodendrocytes was affected, we also performed 
Olig-2 immunostainings on sections of 2-month old cbdnf ko mice. No significant 
decrease in the number of Olig-2 positive cells was found in the striatum of        
2-month old cbdnf ko mice when compared to wild-type mice (unpaired t-test, p> 
0.05, Fig. 13 F). Taken together, these data suggest that BDNF is not required 
for the survival of striatal neurons or of oligodendrocytes during the first 8 weeks 




Fig. 13: The numbers of neurons and oligodendrocytes are analyzed in the striatum of 2-month old cbdnf ko mice. 
Representative images of the striatum of cbdnf ko and wild-type mice immunostained for NeuN (A) and for Olig-2 (B) (10 
µm cryostat sections at 40x magnification). C) Neuronal density in the striatum of cbdnf ko and wild-type mice (n=3 per 
genotype). The neuronal density was higher in the striatum of cbdnf ko mice (p<0.05). D) Number of NeuN positive cells in 
the striatum of cbdnf ko and wild-type mice. No significant differences were detected between the genotypes (p>0.05; n=3 
mice per genotype). E) Oligodendrocyte density in the striatum of cbdnf ko and wild-type mice (n=3 mice per genotype). 
Oligodendrocyte density in cbdnf ko mice appears indistinguishable from control (p>0.05). F) Number of Olig-2 positive 
cells in the striatum of cbdnf ko and wild-type mice. No differences between the genotypes were detected (p> 0.05; n=3 
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3.5  Axonal diameter and myelination in the optic nerve, corpus callosum 
and spinal cord of cbdnf ko mice  
 
Based on the finding that by contrast with the striatum the volume of the 
hippocampus was unchanged, we then tested the possibility that the lack of 
BDNF may affect axonal diameter and myelination, as suggested by previous 
studies on BDNF and TrkB gene deletion (see Cellerino et al., 1997; Minichiello 





Fig. 14: Distribution of myelin in the adult brain. Parasagittal section (10µm) of wild-type brain at P56 were stained with an 
antibody to myelin oligodendrocyte glycoprotein (MOG).  1: Cortex, 2: Hippocampus, 3: Striatum, Arrow:  cortico-striatal 
afferents 
 
As the structure of the striatum does not lend itself to quantitative studies of axon 
diameter, axon numbers and the thickness of myelin sheaths, we turned to an 
electron microscopy (EM) study of the optic nerve, corpus callosum and spinal 
cord. These anatomical regions contain axons running in parallel, a feature that 
greatly facilitates the quantification of myelinated axons, axon density and 
diameter, as well as the thickness of the myelin sheath per axon. To ensure that 
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similar regions were analyzed in each animal, we generated 1 mm brain sections 
with a brain slicer, took always the very same brain region (“section 7/8”) and 
analyzed sagittal sections of the genu of the corpus callosum. In the spinal cord, 
cross sections were examined at the level of the cervical enlargement. The optic 
nerve is sufficiently small and homogenous to analyze entire cross sections of its 
intracranial segment. 
 
Analysis of the optic nerve from cbdnf ko mice revealed no reduction in the cross 
–sectional area relative to wild-type mice (unpaired t-test, p=0.52; Fig. 15). Axons 
of the optic nerve were also counted and no significant differences in the number 
of axons were found in 2-month old cbdnf ko mice compared with wild-type mice 
(unpaired t-test, p=0.82, Fig. 15), indicating that RGC survival is not reduced in 
the absence of BDNF. Consequently, axon density of cbdnf ko mice appears 
indistinguishable from wild-type animals (unpaired t-test, p=0.54, Fig. 15). 
Morphometric analysis of retinal ganglion cell axons in the optic nerve of 2-month 
old cbdnf ko mice revealed no significant difference in the mean size of 
myelinated axons from wild-type mice (unpaired t-test, p>0.05 , Fig. 16).  Further, 
the myelin sheaths of the optic nerve showed no signs of dysmyelination (Fig. 
16) and the myelin sheath thickness of cbdnf ko animals appeared 
indistinguishable from wild-type (unpaired t-test, p>0.05, Fig. 16). The 
relationship between axonal diameter and myelin sheath thickness (g-ratio) 
revealed no significant differences in 2-month old cbdnf ko and wild-type optic 
nerves (unpaired t-test,   p>0.05, Fig. 16). Moreover, the distribution of axonal 
diameter showed a unimodal pattern in both cbdnf ko and control animals 













































Fig. 15: Analysis of the optic nerve of cbdnf ko compared with wild-type animals. A) Light micrographs of semi-thin 
sections stained with toluidine blue of cbdnf ko and control mice. B) Total area of the optic nerve was not significantly 
different from controls (p=0.52). C) The axonal density in the optic nerve of cbdnf ko animals was not significantly different 
from control (p=0.54). D) The total number of retinal ganglion cell axons of cbdnf ko mice was not significantly different 
from controls (p=0.82). Note: Retinal Ganglion cell axons were counted on transverse ultrathin sections of the optic nerve. 
Random fields were photographed, axons were counted from prints, and the axonal density was multiplied by the total 
area of the nerve to determine the total number of axons. The data are presented as the mean ±95% interval confidence 
from the analysis of n mice/genotype. 
 
Morphometric analyses of myelinated fibers in cross sections of the corpus 
callosum of 2-month old cbdnf ko mice also indicated that the size of axons and 
the axonal density was indistinguishable from control animals (unpaired t-test, p> 
0.05, Fig. 17C, D). In addition, the myelin sheath thickness of cbdnf ko mice was 
not significantly different from control animals (unpaired t-test, p>0.05, Fig. 17E).  
Myelinated fibers from the corpus callosum of cbdnf ko and control animals 
revealed no significant increase in the ratio of axon diameter to fiber diameter (g-
ratio) when compared to wild-type mice (unpaired t-test, p>0.05, Fig. 17F). 
Moreover, the frequency histogramm of cbdnf ko and control animals did not 
differ significantly (unpaired t-test, p>0.05, Fig. 17G). To determine whether there 
were structural abnormalities in myelin from the spinal cord of cbdnf ko mice, we 
analyzed white matter tracts at the level of the cervical enlargement. The size of 
axons, the axonal density as well as the myelin sheath of 2-month old cbdnf ko 
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mice was not significantly different from control animals (unpaired t-test; p>0.05; 
Fig. 18). These observations suggest that there are no clear cut differences in 
myelination of cbdnf ko mice and thus indicating, that BDNF does not contribute 
to the growth of axons and of their myelin sheath in the optic nerve, corpus 































Fig. 16: Ultrastructure of the optic nerve in 2-month old cbdnf ko mice. A) Representative EM pictures of myelinated fibers 
in cross sections of the optic nerve of cbdnf ko and control animals. In the mutant the diameter of axons and their density 
appears indistinguishable from control animals. The myelin sheaths in the mutant show no signs of dysmyelination. Each 
EM picture is representative of sections from 4 different animals. B) Axonal diameters of cbdnf ko animals were not 
significantly different from control animals (0.83 ±0.16 vs. 0.85 ±0.12; p=0.78). C) The myelin sheath thickness of cbdnf ko 
animals was not significantly different from control animals (0.15 ±0.01 vs. 0.15 ±0.01; p=0.77). D) The myelinated axons 
of the optic nerve of cbdnf ko and control animals were not significantly different in G-ratio (0.75 ±0.04 vs. 0.77 ±0.02; 
p=0.33). E) Distribution of axonal diameter in the optic nerve. The percentage of axons within a particular size range is 
shown for a total of 455 axons. The frequency histogram showed a unimodal pattern in both cbdnf ko and control animals. 
Note: Axonal density was calculated by counting the total number of myelinated axons in 15 randomly selected non-
overlapping fields of 18.33 µm² from the optic nerve and the axon density was multiplied by the nerve area to determine 
the total number of axons. Axonal diameters and myelin sheath thickness were measured from electronmicrographs using 
AnalysisD software and graphs were generated in GraphPad Prism. The G-ratio is the ratio between axonal diameter and 
total fiber diameter. Statistical analysis: the mean of each parameter for the single animals was calculated in Excel. 
Means obtained from cbdnf ko and control animals were compared using an unpaired t-test. 
  




Fig. 17: Ultrastructure in the corpus callosum in 
2-month old cbdnf ko mice. A) Representative 
EM pictures of myelinated fibers in cross 
sections of the corpus callosum. In the mutant 
the diameter of axons and their density appears 
indistinguishable from control animals. The 
myelin sheaths in the mutant show no signs of 
dysmyelination. B) The density of axons in cbdnf 
ko animals were not significantly different from 
control animals (p=0.57). The number of 
myelinated axons per mm² is presented. C) 
Axonal diameter of mutant mice was not 
significantly different from control animals (0.84 ± 
0.16 vs. 0.85 ±0.12; p=0.88). D) Myelin sheath 
thickness of cbdnf ko mice was not significantly 
different from control animals (0.15 ±0.01 vs. 
0.14 ±0.02; p=0.41). E) Myelinated fibers from 
the corpus callosum of cbdnf ko and control 
animals were not significantly different in G-Ratio 
(0.74 ±0.02 vs. 0.75 ±0.02; p=0.53). F) 
Distribution of axonal diameter in the corpus 
callosum. The percentage of axons within a 
particular size range is shown for a total of 463 
axons. The frequency histogramm of cbdnf ko 
and control animals did not differ significantly. 
Note: Axonal density was calculated by counting 
the total number of myelinated axons in 15 
randomly selected non overlapping fields of 
18.35 µm² from coronal sections in the genu of 
corpus callosum. Axonal diameters and myelin 
sheath thickness were measured from electron-
micrographs using AnalysisD software and 
graphs were generated in GraphPad Prism. The 
G-Ratio is the ratio between axonal diameter and 
total fiber diameter. Statistical analysis: the mean 
of each parameter for the single animals was 
calculated in Exel. Mean obtained from cbdnf ko 
and control animals were compared using an 
















Fig. 18: Ultrastructure of the spinal cord in 2-month old cbdnf ko mice. A) Representative EM pictures of myelinated fibers 
in cross sections of the spinal cord. In the mutant the diameter of axons and the axonal density appears indistinguishable 
from control animals. The myelin sheaths in the mutant show no signs of dysmyelination. B) Axonal density of cbdnf ko 
animals was not significantly different from control animals (p=0.74). The number of myelinated axons per mm² is 
presented. C) Axonal diameter of mutant mice was not significantly different from control animals (p=0.5). D) Myelin 
sheath thickness of cbdnf ko mice was not significantly different from control animals (p=0.8). E) Myelinated fibers from 
the spinal cord of cbdnf ko and control animals were not significantly different in G-Ratio (p=0.74). F) Distribution of axonal 
diameter in the spinal cord. The percentage of axons within a particular size range is shown for a total of 1355 axons. The 
frequency histogram of cbdnf ko and control animals did not differ significantly. Note: Axonal density was calculated by 
counting the total number of myelinated axons in 15 randomly selected non overlapping fields of 315 µm² from the spinal 
cord. Axonal diameters and myelin sheath thickness were measured from electronmicrographs using AnalysisD software 
and graphs were generated in GraphPad Prism. The G-Ratio is the ratio between axonal diameter and total fiber diameter. 
Statistical analysis: the mean of each parameter for the single animals was calculated in Exel. Means obtained from cbdnf 
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In addition to morphometric analyses, we also examined by qRT-PCR possible 
quantitative changes in mRNA expression of Myelin basic protein (MBP), Myelin- 
associated glycoprotein (MAG), Proteolipid protein (PLP), 3`cyclic-nucleotide- 
3`phosphodiesterase (CNPase), Myelin-associated oligodendrocyte basic protein 
(MOBP) and Myelin oligodendrocyte protein (MOG) in the CNS of 2-month old 
cbdnf ko mice compared with wild-type. In line with our morphometric analyses 
no significant differences were found in all tested structures with the exception of 
PLP and MAG in the striatum, and CNPase in the hippocampus (Fig. 19). The 


















Fig. 19: mRNA expression levels of myelin genes in 2-month old cbdnf ko mice as determined by quantitative real-time 
PCR. The relative mRNA levels are normalized for GAPDH mRNA. No marked differences in the expression of myelin 
genes were detected in the CNS of 2-month old cbdnf ko mice compared with wild-type, except for PLP and MAG in the 
striatum, and CNPase in the hippocampus. All results are presented as a mean ±SEM derived from 4-7 individual cbdnf 
ko and control animals (*, p<0.05; **, p<0.01; unpaired t-test). Black bars are cbdnf ko and white wild-type. MBP: Myelin-
basic protein; MAG: Myelin-associated glycoprotein; PLP: Proteolipid protein; CNPase: 3`cyclic-nucleotide-3`phosphodi-
esterase; MOBP: Myelin-associated oligodendrocyte basic protein; MOG: Myelin oligodendrocyte protein.  
NB: 1) No significant decrease in the expression of MBP was detected in the striatum of 2-month old cbdnf ko mice 
compared with wild-type, as the values obtained for different wild-type animals was unexplainably high. To test if the 
decrease in the expression of MBP mRNA in the striatum of 2-month old cbdnf ko animals is significant, the levels of MBP 
should be further investigated by increasing the number of animals. 2) mRNA expression of MBP, MAG, PLP, CNPase, 
MOBP, and MOG was also examined in the brainstem and spinal cord of 2-month old cbdnf ko and wild-type animals by 
qRT-PCR. As observed for MBP mRNA values in the wild-type animals, we also found a high variability both in wild-type 
and cbdnf ko mice in brainstem and spinal cord for all myelin marker. The reason for this high variability remains unclear. 
These data were not included into the graph. Clearly, additional measurements are needed. 
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3.6  mRNA levels of NGF, NT3 and NT4 in cbdnf ko mice 
 
To test the possibility that the near complete absence of BDNF in the adult CNS 
may trigger compensatory changes in the levels of expression of the other 
neurotrophins, we determined mRNA levels of NGF, NT3 and NT4 by qRT-PCR 
in the brain of 2-month old cbdnf ko and wild-type animals. No significant 
differences in the expression of neurotrophin genes were detected in the CNS, 
with the exception of NGF in the olfactory bulb and cerebellum, and NT3 in the 
cortex (Fig. 20). The reasons for these expression profile changes in the mutant 
are unclear. The expression of NT3 and NT4 were not significantly changed in 
the hippocampus of 2-month old cbdnf ko mice compared with wild-type (Fig. 20). 
It is conceivable that NT4 and NT3 may not exert a compensatory role in the 




Fig. 20: mRNA expression levels of neurotrophin genes in 2-month old cbdnf ko mice as determined by quantitative real-
time PCR. The relative mRNA levels are normalized for GAPDH mRNA. No marked differences in the expression of 
neurotrophin genes were detected in the CNS, with the exception of NGF in the olfactory bulb and cerebellum, and NT3 in 
the cortex. All results are presented as a mean ±SEM derived from 5-7 individual cbdnf ko and control animals (*, p<0.05; 
unpaired t-test). Black bars are cbdnf ko and white wild-type. NT3: neurotrophin-3; NT4: neurotrophin-4; NGF: nerve 
growth factor. 
 
NB: No significant decrease in the expression of NGF was detected in cortex, striatum and hippocampus of 2-month old 
cbdnf ko mice compared with wild-type, as the values obtained for different control animals was unexplainably high. To 
test if the decrease in the expression of NGF mRNA in the cortex, striatum and hippocampus of 2-month old cbdnf ko 
animals is significant, the levels of NGF mRNA should be further investigated by increasing the number of animals. The 
same applies for NT4 in the olfactory bulb, striatum, midbrain and cerebellum, as the spread of values obtained for cbdnf 
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3.7 Biosynthesis, storage and secretion of BDNF in the CNS 
 
Over-expression studies suggested that pro-BDNF is released from central 
neurons in an activity dependent manner, that it is extracellularly cleaved via a 
TPA-dependent pathway and that it contributes to hippocampal LTD (Lee et al., 
2001; Pang et al., 2004; Woo et al., 2005). In collaboration with my colleague Dr. 
Tomoya Matsumoto, we examined the question of endogenous pro-versus 
mature BDNF in the adult brain, as well as in cultured neurons (see also 
Matsumoto et al., 2008).  
 
As BDNF is a protein of extremely low abundance, even in the adult brain, 
reliable detection of BDNF by Western blot techniques (WB) requires rigorous 
controls, including in particular the cbdnf ko mice generated in this study. In 
addition, due to the fact that BDNF induces numerous genes in the CNS the 
mere absence of BDNF may not be a sufficient specifity control. As an added 
control, we thus used a bdnf-myc mouse line previously generated in our 
















Fig. 22:  Generating bdnf-myc knock-in mice: bdnf-myc knock-in (bdnf-myc) mice were generated by substituting exon VIII 
of the bdnf gene with a human c-myc tagged version of the gene. c-Myc was added at the C-terminus of wild-type BDNF 
following deletion of the last 3 amino acids. 
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Western blots performed with hippocampal extracts of 8-week old animals and 
BDNF antibodies showed a weak ~14 kDa signal that was absent in cbdnf ko or 
shifted in size in bdnf-myc extracts, while pro-BDNF was undetectable (Fig. 23A, 
left). We then compared the levels of BDNF determined by Western blot 
quantification with those obtained by a 2-site immunoassay (Kolbeck et al., 1999) 
and found the results to be in reasonable agreement (Fig. 23C). In an attempt to 
detect pro-BDNF, we first immunoprecipitated hippocampal lysates with a BDNF 
monoclonal antibody (mAb#9) that recognises both pro- and mature BDNF (Fig. 
24A, B), followed by Western blot using BDNF polyclonal antibodies. This 
enrichment allowed the detection of a weak, but specific pro-BDNF signal of 
about 30-35 kDa, and quantification indicated that pro-BDNF levels are less than 
10% of those of BDNF (Fig. 23B, D). These results were confirmed using either 
anti-pro-BDNF or anti-Myc antibodies (Fig. 23A, B). We next performed pulse-
chase experiments using cultured hippocampal neurons and found that pro-
BDNF is quantitatively converted to BDNF by the end of the chase period (Fig. 
24A, right). Identical results were obtained when incubating the neurons with 
mAb#9 (Fig. 24B, left), indicating that pro-BDNF is a transient biosynthetic 
intermediate and undergoes intracellular processing. These results were 
confirmed using dissociated cultured neurons prepared from bdnf-myc animals 
(Fig. 24B, right). To examine the activity-dependent secretion of BDNF, we 
exposed the neurons to bicuculline, a GABA-A receptor inhibitor. This led to a 
marked increase of BDNF both in the medium and within the cells (Fig. 24C) in 
line with previous results indicating that the activation of synaptic NMDA 
receptors increases the transcription of bdnf (Hardingham et al., 2002). Under 
these conditions, barely detectable levels of pro-BDNF were observed in the cell 
lysates (Fig. 24C).  
 
 







Fig. 23: Detection of BDNF in the mouse hippocampus. (A) Western blot with the indicated antibodies were performed 
with hippocampal extracts prepared from mice with the indicated genotypes. In the left or middle panel, note a signal of a 
size roughly corresponding to pro-BDNF or to mature BDNF, but also in present KO lysates. (B) Immunoprecipitation of 
hippocampal extracts from the indicated animals with the indicated antibodies followed by Western blot with the pAbN20 
polyclonal antibody was performed. (C) BDNF concentrations were determined as in (A, left) and a 2-site immunoassay 
with 2 different monoclonal anti-BDNF antibodies (mAb#1 and mAb#9). (D) Ratio of pro-BDNF and BDNF. In (A, B), 
cleavage-resistant pro-BDNF and BDNF-myc (produced by COS7 cells), or recombinant purified BDNF and non-
glycosylated pro-BDNF (produced in E coli) were used as a control. Error bars, SEM. IP: Immunprecipitation; IB: 
Immunoblot; WB: Western blot. 
 







Fig. 24: Intracellular processing of pro-BDNF in neurons. A) COS7 cells transfected with the indicated constructs and 
cultured mouse hippocampal neurons (15 days in vitro, DIV) were radiolabeled with [35S]methionine/cysteine for 2 hours 
and chased for the indicated times. Cell lysates and media were immunoprecipitated with mAb#9, followed by SDS-PAGE. 
(B) Using cultured wt and bdnf-myc hippocampal neurons (15DIV), pulse-chase experiments were performed as in (A), 
but in the presence of mAB#9. Cell lysates were immunoprecipitated with the indicated antibodies. (C) Cultured 
hippocampal neurons were treated with bicuculline (50 μM) in the presence or absence of mAb#9 (5 μg/ml) for 1 day (14-
15 DIV). Cell lysates and media were immunoprecipitated with mAb#9, followed by WB with pAbN20. Recombinant 
purified BDNF and cleavage-resistant pro-BDNF were used as a control. 
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Finally, we tested a previous suggestion that pro-BDNF would play a crucial role 
in long-term depression (LTD) (Loo et al., 2005; Woo et al., 2005) through the 
neurotrophin receptor p75NTR (Woo et al., 2006; Rosch et al., 2006). If pro-BDNF 
were to be released from neurons, this would be an attractive possibility as 
recombinant pro-BDNF has been shown to bind to p75NTR with high affinity in the 
presence of sortilin (Teng et al., 2007). However, we found LTD to be unaffected 
in slices prepared from cbdnf KO animals (Fig. 25A). As expected (Poo et al., 
2001), long-term potentiation (LTP) was compromised in cbdnf KO slices (n=3 
slices from 2 mice) compared with wt samples (n=3 from 2) (Fig. 25B).  
                     
 
Fig. 25: BDNF is necessary for inducing 
hippocampal CA3→CA1 LTP, but not LTD. (A) 
Summary graph of LTD experiments with 2-3-
week old wt (n=8 slices from 4 mice) and cbdnf 
KO mice (n=9; 4 mice). Symbols represent 
average responses plotted every minute. (Inset) 
Averaged single traces of an individual 
experiment just before and 55-60 minutes after 
low-frequency stimulation (LFS; 15 minutes, 1 Hz) 
of wt and cbdnf KO mice. (B) Single sample of an 
LTD/LTP experiment. Slope is plotted against 
time. After 20 minutes of baseline recording, the 
same LFS as in (A) was applied. After 60 minutes, 
the signal was adjusted back to the original 
fEPSP values (100% pre-LFS baseline). Three 
theta burst stimulation (TBS; 100 Hz, 200 µs 
duration, 200 ms inter-bust interval, 10 s inter-
stimulus interval) were subsequently applied. 
fEPSP size and paired-pulse-facilitation was not 








In the present study we attempted a global BDNF deletion in the CNS by 
crossing floxed bdnf mice with mice expressing Cre from the tau locus. Our 
results show that mice survive several months after birth with nearly undetectable 
levels of BDNF protein in the CNS. As BDNF levels are very low even in the 
normal adult brain, lysate of cbdnf ko mice also served as a key control in 
biochemical experiments examining the molecular weight and quantity of BDNF 
in the brain (see below 4.4).  
 
Two months old cbdnf ko mice were hyperactive when stressed, had higher 
levels of anxiety when evaluated in the light/dark exploration test and displayed a 
clasping phenotype similar to that observed in mouse models of Huntington`s 
disease. Additionally, female cbdnf ko mice developed mature onset obesity. 
Brain weight of two months old cbdnf ko mice was reduced by about 20% 
compared with wild-type. Comparative volume measurements of major brain 
areas indicated that the striatum (36.5%) and cortex (20%), but not the 
hippocampus of 2-month old cbdnf ko mice were significantly reduced in volume. 
To determine whether the decrease in striatal volume was caused by cell loss, 
neurons and oligodendrocytes were counted. No significant differences in their 
numbers were found, but the neuronal density was increased. Based on the 
finding that the volume of the hippocampus was unchanged, we initially 
hypothesized that the volume reduction of the striatum could be explained by a 
decrease in the size of axonal diameter of the cortico-striatal afferents, with a 
corresponding decrease in myelination. This possibility was suggested by 
previous findings, indicating a pro-myelinating role of BDNF through TrkB 
signalling (Cellerino et al., 1997; Medina et al., 2004). As the structure of the 
striatum does not lend itself to quantify axonal diameters, axonal numbers, and 
thickness of myelin sheaths of the cortico-striatal afferents, we turned to an 
electron microscopy study using the optic nerve, corpus callosum and spinal cord. 
However, no significant differences in axonal diameter and myelination were 
observed in these structures, suggesting that BDNF may not be required for the 
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growth and maintenance of axons and their myelin sheath. This result was 
further confirmed by a qRT-PCR analysis of myelin genes. In all tested structures, 
no consistent changes were observed, except for PLP and MAG in the striatum 
and CNPase in the hippocampus, for reasons that are unclear. mRNA levels of 
NGF, NT3 and NT4 were also determined by qRT-PCR and no significant 
increase of NT4 and/or NT3 mRNA expression was found in the hippocampus, 
indicating that NT4 (also known to activate TrkB) and NT3 may not exert a 
compensatory role and contribute to the lack of hippocampal volume reduction.  
 
4.1 cbdnf ko mice 
4.1.1 Tau 
Tau is a low-molecular-weight microtubule associated protein that is abundant in 
the CNS, where it is expressed predominantly in axons of neurons (Cleveland et 
al., 1977; Binder et al., 1985) tho it is also found in oligodendrocytes (LoPresti et 
al., 1995). Tau regulates the assembly and stability of microtubules (Weingarten 
et al., 1975; Cleveland et al., 1977), and this microtubule-binding function of Tau 
is negatively regulated by phosphorylation (Drechsel et al., 1992; Biernat et al., 
1993; Bramblett et al., 1993). However, a mouse mutant null for the tau gene did 
not reveal any defects in regard to axonal growth or maintenance (Harada et al., 
1994). Work from our laboratory has previously shown that the endogenous tau 
promoter drives expression of GFP soon, and long after neurons have become 
postmitotic (Tucker et al, 2001). Intercrosses between the tau::Cre and Cre-
activatable reporter animals resulted in offsprings with recombination either 
restricted to the nervous system or throughout the entire embryo, indicating 
expression of Tau early in development. The percentage of neuron-specific 
excision was dependent on the Cre reporter system used. In spite of the 
observed variability, these data suggested that the tau::Cre mouse line can be 
used for pan-neuronal recombination of floxed alleles throughout the mouse 
nervous system (Korets-Smith et al., 2004). Based on these studies, we 
expected the elimination of BDNF specifically in most postmitotic neurons of the 
central and peripheral nervous system. 
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4.1.2 Generation of cbdnf ko mice 
Mutants generated in the present study were in a mixed genetic backround 
(Sv129/C57/Bl6) and fell into 3 categories: bdnf full knockout (19%), bdnf mosaic 
(5%) and tissue - specific bdnf knockout mice (1%). This result indicated that in 
the majority of the progeny, the floxed bdnf allele was excised already at the 
zygote stage or in the early postimplantation embryo and only in a minority in a 
neuron-specific manner. However, mutants generated in a C57/Bl6 backround 
were exclusively bdnf full knockout mice. Recently, Korets-Smith et al. (2004) 
demonstrated that the genetic background of parental mice and the position in 
the genome of the loxP target allele can each contribute to differences in the 
exact pattern of recombination. In the present study, we confirmed that Cre-
mediated recombination can be influenced by the strain background of the mice, 
raising the question of how strain background could exert this effect. One 
possibility is that modifier loci, present as different alleles in the different strains, 
alter a low basal level of Tau expression. Alternatively, these modifier loci might 
not influence expression of the wild-type tau locus, but instead alter that of the 
tau::Cre allele, which contains sequences not normally found at this locus. A final 
possibility is that the activity of the Cre recombinase itself can be modulated by 
factors present in some strains of mice but not in others. An alternative 
explanation is that the floxed bdnf gene in the C57/Bl6 backround itself is 
somehow more susceptible to recombination than the floxed bdnf gene in the 
Sv129/C57/Bl6 backround. Consequently, the levels of Cre known to be present 
early in development are sufficient to trigger recombination of the floxed bdnf 
allele in the C57/Bl6, but less efficient in the mixed backround. It is conceivable, 
although speculative, that local differences in chromatin structure can alter the 
efficiency of recombinase activity. If this were to be the case, great care should 
be exerted when extrapolating from results obtained with reporter lines when the 
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4.1.3 cbdnf ko mice compared with other conditional bdnf knockout mice 
 
A fundamental difference between previously reported conditional bdnf knockout 
and the newly generated cbdnf ko mice is the extent of recombination of the 
floxed bdnf allele. In previous studies, the floxed bdnf allele was excised in an 
area- and cell type specific manner, like for example in the Emx-BDNFKO mouse, 
in which BDNF was excised in excitatory neurons and glia cells of the cortex, 
hippocampus and amygdala (E10.5) (Gorski et al., 2002; Gorski et al., 2003; 
Baquet et al., 2004), or in the Wnt-BDNFKO mouse, in which BDNF was excised 
in neurons of the midbrain-hindbrain (E8.5) (Baquet et al., 2005; Danielian et al., 
1998), or in the CamKII-BDNFKO mouse, in which BDNF was postnatally deleted 
in neurons of the hippocampus, cortex, hypothalamus and brainstem (P21) (Rios 
et al., 2001; Zakharenko et al., 2003; Monteggia et al., 2004; Monteggia et al., 
2007). In the present study the floxed bdnf allele was globally deleted throughout 
the nervous system, already during development. Interestingly, Chan et al. 
(2006) used the Nestin-Cre deleter to generate mice with a virtual depletion of 
BDNF across the brain. However, although their approach is quite similar to ours, 
significant differences exist between these two genetic approaches. In particular 
the Cre construct used by Chan et al. (2006) directs the expression of Cre to the 
CNS, but not the PNS (Zimmerman et al., 1994). Therefore, BDNF expression is 
unaffected in neurons of the PNS. Tau, on the other hand is expressed in all 
postmitotic neurons of the CNS and PNS with the consequence that BDNF 
expression is absent from all CNS and PNS neurons of cbdnf ko mice. This is 
important, since BDNF can then not be imported by anterograde transport from 
the PNS to the CNS in cbdnf ko mice, while this is still the case in the Nestin-
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4.1.4 BDNF protein measurement (ELISA) 
 
A precise delineation of the numerous biological roles of BDNF necessitates 
reliable information on the localization and amount of BDNF protein in the 
nervous system. Measuring BDNF protein levels reliably is critically dependent 
on the availability of reagents such as monoclonal antibodies with established 
specificity. In addition to the problem of antibody specificity, it has been shown 
that the use of an acidic extraction buffer containing high salt and detergent in-
crease the availability of BDNF in tissue extracts (Barde et al., 1982; Hofer and 
Barde, 1988; Nawa et al., 1995). It appears likely that upon basic or acidic pH 
treatment, this basic growth factor may dissociate from binding proteins present 
in the extracts, resulting in increased availability for antibody binding.  
 
Most existing BDNF immunoassays are based on the use of polyclonal antisera 
to BDNF (Nawa et al., 1995; Zhou et al., 1996; Katoh-Semba et al., 1997), 
sometimes used in combination with a monoclonal antibody (mAb) (Radka et al., 
1996; Inoue et al., 1997). Although BDNF is a homodimeric protein, it has not 
been possible to use the same mAb as a reagent in a sandwich immunoassay, 
as has been possible with NGF (Korsching and Thoenen, 1983) and NT3 
(Shintani et al., 1993). Obtaining useful BDNF mAbs is a difficult task, in part due 
to the very high conservation of this protein between species: the sequence of 
processed, biologically active BDNF is identical in all mammals. However, 
Kolbeck et al. (1999) managed to produce two monoclonal antibodies 
recognizing two different epitopes of BDNF, which can be used in an 
immunoassay to measure BDNF protein levels with a satisfactory degree of 
sensitivity and specificity. 
 
To measure the remaining levels of BDNF in the mutants of fbdnfxtau::Cre litters, 
we used in the present study the BDNF immunoassay system published by 
Kolbeck et al. (1999). We found a ≥ 95% reduction of BDNF protein levels 
throughout the brain of 2-month old mutants compared with wild-type littermates. 
The remaining levels of BDNF (≤ 5%) may be explained by the expression of 
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BDNF in endothelial cells, vasculature and astrocytes (Binder et al., 1985; 
LoPresti et al., 1995; Liem et al., 2001; Nakahashi et al., 2000; Donovan et al., 
2000; Wang et al., 2006; Riley et al., 2004; Forman et al., 2005), since Tau is not 
expressed in those cell types. Conversely, due to the likely expression of tau in 
oligodendrocytes (Dai et al., 2003), we cannot exclude that BDNF is exclusively 
expressed in neurons though in situ hybridization experiments indicate that 
neurons are the primary sites of BDNF expression (Hofer et al., 1990). We note 
that the levels of BDNF measured in the CNS of 2-month old wild-type        
fbdnfxtau::Cre litters were similar to those published by Kolbeck et al. (1999), 
who measured BDNF protein levels in the CNS of 3 week old wild-type mice.  
 
Further, our hippocampal values for BDNF (195 ng/g) are also similar to those 
previously determined in the adult hippocampus by Radka et al. (1996) (rat: 256 
ng/g; mouse: 181 ng/g) and Narisawa-Saito and Nawa (1996) (rat: 270 ng/g) 
using BDNF immunoassays based on the combination of a mAb with a polyclonal 
antiserum or of two polyclonal antisera, respectively. However, our measured 
hippocampal BDNF protein levels are considerably higher than those reported by 
others in the adult rat hippocampus [14.5 ng/g (Zhou et al., 1996); 19.9 ng/g 
(Nawa et al., 1995); 5.4 ng/g (Katoh-Semba et al., 1997); 3 ng/g (Scaccianoce et 
al., 2003); 9 ng/g (Angelucci et al., 2000); 15 ng/g (Ickes et al., 2000); 60 ng/g 
(Rudge et al., 1998)]. Most likely, different types of BDNF extraction procedures 
and the correction of BDNF yields account for these discrepancies.  
 
The relatively high levels of BDNF protein found in the striatum and the spinal 
cord, areas of the CNS known to express very low levels of BDNF mRNA, can be 
explained by the anterograde transport of BDNF (Altar et al., 1997; Zhou and 
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4.1.5 Why do cbdnf ko mice survive and breath normally? 
 
Erickson et al. (1996) demonstrated that BDNF is required for development of 
normal respiratory activity and that newborn bdnf knockout mice exhibit severely 
depressed and irregular breathing. This abnormal respiratory phenotype is 
related in part to the loss of BDNF-dependent chemoafferent neurons in the 
pedrosal ganglia that provide excitatory drive to the respiratory central pattern 
generator. In addition, BDNF is also known to modulate the responsiveness of 
second-order sensory neurons in the nucleus tractus solitarius (nTS) to 
glutamatergic stimulation, an effect of BDNF that can be mimicked by NT4, and 
which is blocked by the Trk tyrosine kinase inhibitor K252a, indicating the 
requirement for TrkB receptor activation. These findings could explain why the 
loss of BDNF may result in a depression of motor output from the brainstem 
respiratory rhythm generator and suggest that BDNF play an important role in 
regulating excitatory transmission at primary afferent synapses (Balkowiec and 
Katz, 1998; 2000; Thoby-Brisson et al., 2003; Baker-Herman et al., 2004). 
Therefore, the lethality associated with the bdnf knockout phenotype may result 
from deficits in central respiratory output (Balkowiec and Katz, 1998), as well as 
excitatory chemoafferent drive. Moreover, the absence of baroreceptor 
innervation in bdnf knockout mice suggests that cardiovascular homeostasis is 
likely to be disrupted in these animals as well (Brady et al., 1999).  
 
A possible answer to the question why cbdnf ko mice survive in contrast to bdnf 
full knockout mice, is based on the results that the total amount of BDNF protein 
in the heart of cbdnf ko mice was not significantly altered compared with that of 
wild-type mice. This finding suggests that baroreceptor afferents from the nodose 
ganglia of cbdnf ko mice are likely to innervate the aortic arch as in wild-type 
animals and that cardiovascular homeostasis may be approximately normal in 
cbdnf ko mice (Erickson et al., 1996; Brady et al., 1999; Hellard et al., 2004; 
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4.2 Histological analysis of 2 months old cbdnf ko mice 
 
4.2.1 Volume reduction of the striatum 
 
Our results indicate that striatal volume reduction of 2-month old cbdnf ko mice is 
not due a cell loss or a defect of axonal myelination. Similarly, Baquet et al. 
(2004) failed to detect neuronal losses in the striatum of 4 months old Emx-
BDNFKO mice. The lack of a consistent result clearly indicating that myelination is 
affected is unexpected in view of previous analysis of bdnf full knockout and 
TrkBNestinCre conditional knockout mice (Cellerino et al., 1997; Medina et al., 
2004). In bdnf full knockout mice, a reduction in the size of retinal ganglion cell 
axons was shown to be accompanied by hypomyelination of the optic nerve. 
However, the interpretation of the phenotype of bdnf full knockout mice is 
complicated by their poor health, even if peripheral myelination was found to be 
normal (Cellerino et al., 1997). Our findings may be explained by a develop-
mental delay of bdnf full knockout mice, leading to a retardation of CNS 
myelination, known to largely occur postnatally in rodents. TrkBNestinCre 
conditional knockout mice, in which TrkB is deleted during development from all 
neuronal and glial precursors of the CNS, were characterized by a significant 
reduction in the number of myelinated axons and myelin sheaths in the corpus 
callosum and CA1 region of the hippocampus (Medina et al., 2004). From this 
study it was concluded that TrkB signaling regulates myelination in the CNS and 
that this may occur, at least in part, through the regulation of oligodendrocyte 
differentiation. Interestingly, deletion of TrkB at P20 does not affect oligo-
dendrocyte differentiation nor CNS myelination in the CA1 region of the 
hippocampus as observed in the TrkBCaMKIICre mutant mice (Minichiello et al, 
1999), suggesting that TrkB signaling in axons regulates oligodendrocyte 
myelination before P20, and/or that TrkB signaling in oligodendrocytes is 
sufficient to mediate their proper differentiation and myelination function. A 
possible explanation for the observed difference between cbdnf ko and 
TrkBNestinCre mice may also be that alternate TrkB ligands  compensate for the 
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loss of BDNF, and therefore supporting proper differentiation and myelination 
function of oligodendrocytes in cbdnf ko mice. 
  
4.2.2 mRNA levels of NGF, NT3 and NT4 in cbdnf ko mice 
In the present study, we tested the possibility that the virtual absence of BDNF in 
the adult CNS may trigger compensatory changes in the expression levels of 
other neurotrophins. We found that mRNA levels of NT3 and NT4 were not 
significantly changed in the hippocampus of 2-month old cbdnf ko mice 
compared with the wild-type. It is thus unlikely that NT4 (also known to activate 
TrkB) and NT3 may exert a compensatory role in the hippocampus of 2-month 
old cbdnf ko mice and contribute to the lack of hippocampal volume reduction. 
While Baquet et al. (2004) also found that the gross morphology of the 
hippocampus in 4 months old Emx-BDNFKO mice was unchanged, they explained 
the lack of hippocampal volume reduction by 2-fold increase of NT3 expression 
as well as by the anterograde transport of BDNF from the amygdala, thalamus, 
hypothalamus and ventral tegmental area (Baquet et al., 2004). 
 
Our findings on the lack of effects of BDNF deprivation on hippocampal volume 
are in accordance with that of Baquet et al. (2004), but contrast with that of Chen 
et al. (2006), who found a significant, but very small decrease of hippocampal 
volume in BDNFMet/Met knock-in mice. Importantly, BDNFMet protein levels were 
normal in the brain of 2-month old BDNFMet/Met mice compared with wild-type 
mice. However, the distribution of BDNFMet protein to neuronal dendrites and its 
activity-dependent secretion from neurons was reported to be decreased, though 
these difficult experiments would need to be independently confirmed. Clearly, 
more needs to be learned about the biosynthesis of wild-type BDNF versus 
BDNFMet protein (see also 4.4), while it has been suggested that BDNFMet may 
not interact as well as wild-type BDNF with sortilin, thought to be important for 
the intracellular trafficking of BDNF (Chen et al., 2005). It is surprising, that 
potentially small changes in the secretion of BDNF (Chen et al., 2006) lead to a 
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morphological hippocampal phenotype not seen in the almost complete absence 
of BDNF (this study). 
 
4.2.3 Role of BDNF in adult neurogenesis 
Because of the extensive literature indicating that granule cells of the 
hippocampus undergo neurogenesis throughout life, several studies have 
investigated whether BDNF might influence neurogenesis. For example, 
Benraiss et al. (2001) showed that increasing BDNF in the adult subventricular 
zone using an adenovirus approach increased the number of new neurons in 
several brain areas outside the hippocampus. Peneca et al. (2001) showed that 
i.c.v. BDNF led to increased numbers of new neurons in several areas adjacent 
to the ventricles, such as the striatum, septum, and the thalamus. In the dentate 
gyrus, Lee et al. (2000) showed that dietary restriction increased BDNF, and that 
there was an increase in the dentate gyrus neurogenesis as well. Katoh-Semba 
et al. (2002) reported that riluzole, a drug currently approved for amyotrophic 
lateral sclerosis, increased BDNF levels in the hippocampus, and increased 
proliferation of granule cells. Consistent with a role of BDNF, they further found 
that infusion of an antibody to BDNF into the ventricles blocked the increase in 
proliferation. In heterozygote bdnf knockout mice, Linnarsson et al. (2000) 
showed that the number of new cells in the dentate gyrus was decreased. Based 
on these studies it seems that BDNF may play an important role in adult 
neurogenesis. We found no significant volume reduction in the dentate gyrus of 
2-month old cbdnf ko mice. Therefore it may appear unlikely that endogenous 
BDNF plays a major role in adult neurogenesis in the dentate gyrus. This 
conclusion relies on the assumption that newly born neurons in the dentate gyrus 
significantly contribute to maintaining the size of the adult dentate gyrus. New 
results suggest however that the contribution of newly generated neurons stably 
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4.3  Phenotype of cbdnf ko mice 
 
4.3.1 Clasping behavior 
cbdnf ko mice exhibit clasping of hindlimbs, a stereotyped behavioral phenotype 
indicative of striatal neuronal dysfunction that becomes increasingly severe as 
these mice age. A similar clasping phenotype has been seen in Huntington´s 
disease (HD) model mice (Carter et al., 1999; Auerbach et al., 2001; Guidetti et 
al., 2001), as well as in Emx-BDNFKO mice (Baquet et al., 2004). Interestingly, 
Emx-BDNFKO mice did not perform poorly on rotarod tests, whereas HD model 
mice exhibit both clasping phenotype and poor rotarod test performance. These 
similarities and subtle differences in behavioral phenotypes between HD model- 
and Emx-BDNFKO mice opened the possibility to closely compare these two 
model systems to identify possible neurological foundations for BDNF dependent 
aspects of the HD phenotype. From microarray-based comparisons of striatal 
RNAs in early human Huntington´s disease with several rodent models of HD, 
Strand et al. (2007) reached the unexpected conclusion that depletion of BDNF 
provides the best murine mimic for the striatal changes observed in early HD, 
especially in mice, where the BDNF gene is specifically deleted in the cortex 
(Baquet et al., 2004; Gorski et al., 2003). Neither the R6/2 mouse, nor 3-NP-
treated, MPTP-treated and PGC1-α knockout mice – all of which show HD-like 
pathology - do as well as Emx-BDNFKO mice in mimicking HD-associated 
changes in gene expression. Strand et al. (2007) suggested that decreased 
synthesis and anterograde transport of BDNF may underlie the characteristic 
striatal pathology of HD. These data supported the conclusion that dysfunction 
and loss of striatal neurons does not result from the expression of mutant 
huntingtin (htt) in striatal neurons, but from the decreased trophic support from 
cortical cells that express mutant htt.  
 
With regard to functional aspects, 2 ‘classic’ forms of long-term synaptic plasticity 
- LTD and LTP - have been described at corticostriatal synapses (Calabresi et al., 
1992). Both seem to underlie motor skill learning, cognitive performances and 
reward mechanisms. Following LTP induction, it is possible to reverse the 
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previously potentiated synapse to pre-LTP levels. This last form of synaptic 
plasticity, termed ‘depotentiation’, appears to represent the neural correlate of 
‘forgetting’ and and is thought to help improving circuit dynamics (Picconi et al., 
2003). However, alterations in the induction and reversal of synaptic plasticity 
have been demonstrated in both 3-NP-treated rats and the genetic R6/2 mouse 
model of HD. Striatal medium-sized spiny neuron recordings from both of these 
models showed a normal LTP, but a failure to depotentiate their synapses after a 
low-frequency stimulation protocol (Picconi et al., 2006). This inability to reverse 
synaptic strength to pre-LTP levels leads to altered circuit efficiency during either 
information storage or physiological synaptic forgetting, and may account for the 
impaired behavioural flexibility described in HD patients at early clinical stages. 
Interestingly, although cholinergic interneuron recordings from control animals 
showed a robust LTP, they did not demonstrate LTP in either 3-NP animals or 
HD R6/2 mice (Picconi et al., 2006). As the synaptic depotentiation normally 
seen in medium-sized spiny neurons depends upon the activation of muscarinic 
receptors, it is conceivable that in HD models, the lack of potentiation of 
cholinergic interneurons accounts for the absence of depotentiation in spiny 
neurons. As Strand et al. (2007) described conditional bdnf knockout mice as the 
best murine mimic of striatal changes in early HD, cbdnf ko mice may offer an 
interesting additional opportunity to test this hypothesis. 
 
4.3.2 Obesity 
Obesity phenotypes have been observed in bdnf heterozygous mice and in mice 
in which the bdnf gene has been deleted in excitatory neurons in the adult brain 
(Lyons et al., 1999; Kernie et al., 2000; Rios et al., 2001).  Even mouse mutants 
that express TrkB at a quarter of the normal amount showed hyperphagia and 
excessive weight gain (Xu et al., 2004). These studies indicated that the 
BDNF/TrkB signaling participates in the regulation of energy balance and feeding 
behavior. Surprisingly, in the present study, we found that only female cbdnf ko 
mice became obese over time, whereas males did not. These results were not in 
line with previous studies (Rios et al., 2001; Xu et al., 2004). However, most 
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mammals show gender dimorphisms in body mass and differently regulate 
energy homeostasis and substrate utilization, and our results suggest that BDNF 
might be involved in regulating these differences. 
 
4.3.3 Activity 
cbdnf ko mice had a substantial increase in locomotor activity when stressed but 
not at baseline, suggesting a role for BDNF in the regulation of anxiety-related 
behavior (4.3.4). Interestingly, increased spontaneous activity has been 
repeatedly observed in all BDNF mutants (Kernie et al., 2000; Lyons et al., 1999; 
Monteggia et al., 2004; Rios et al., 2001), except one (Gorski et al., 2003). 
Hyperlocomotion and impulsivity was also reported for the TrkB-CRE and TrkB-
Shc mutants (Minichiello et al., 1998; Minichiello et al., 1999; Zorner et al., 2003). 
Although largely unknown, factors such as serotoninergic abnormalities, inner 
ear defect or aggravated stress response have all been suggested as possible 
origins explaining hyperactive behavior (Lyons et al., 1999; Minichiello et al., 
1998; Zorner et al., 2003).  Interestingly, hyperactivity is also a feature of mice 
lacking expression of 5-HT2C (Nonogaki et al., 2003), a serotonin receptor 
subtype associated with depression (Gurevich et al., 2002; Lerer et al., 2001). As 
BDNF has been suggested to be important for proper serotonergic 
neurotransmission (Lyons et al., 1999; Mamounas et al., 1995; Siuciak et al., 
1998), a careful examination of this system in the mutants is warranted. 
 
4.3.4 Anxiety 
Anxiety is a complex phenotype, mediated by multiple brain nuclei, including the 
amygdala, prefrontal and cingulate cortices, and the hippocampus (Gray, 1981; 
Sandford et al., 2000). Additionally, it is susceptible to alterations via numerous 
drugs that target multiple neurotransmitter receptor systems, including GABA and 
monoamines (Argyropoulos et al., 2000). BDNF is known to influence 
differentiation and function of GABAergic, serotonergic, dopaminergic and 
noradrenergic neurons suggesting that systems modulating anxiety could be 
affected by loss of BDNF (Altar et al., 1994; Sklair-Tavron and Nestler, 1995).  In 
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our study, we used the light/dark exploration test to determine whether the lack of 
BDNF in cbdnf ko mice altered anxiety. Significant differences were found in the 
number of white box entries, and the time spent in the white chamber and we 
concluded that deleting BDNF early in development result in increased anxiety 
level. In line with this, postnatal, brain-restricted BDNF mutant mice (CamKII-
BDNFKO) exhibit higher levels of anxiety in the light/dark exploration test (Rios et 
al., 2001) and transgenic mice overexpressing TrkB exhibit reduced anxiety-like 
behavior in the light/dark exploration test (Koponen et al., 2004). As TrkB also 
serves as a receptor for NT4, which like BDNF augments monoaminergic 
systems (Altar et al., 1994), it is not clear whether those changes are entirely 
associated with BDNF signaling. A better understanding of the role of BDNF in 
anxiety related behavior could be achieved by testing the efficacy of anxiolytic 
agents in our cbdnf ko animals. 
 
4.4  Biosynthesis, storage and secretion of BDNF 
 
Recent studies have suggested that pro-BDNF is released from central neurons 
in an activity-dependent manner and that it is crucial in long-term depression 
(LTD) (Mowla et al., 1999; 2001; Chen et al., 2004; Woo et al., 2005). Pro-BDNF 
was also suggested to be cleaved extracellulary after release via a TPA-
dependent pathway (Pang et al., 2004), with the suggestion that the secretion of 
TPA may also be activity dependent. However, our detailed studies revealed no 
evidence for pro-BDNF being released from cultured hippocampal neurons. In 
addition, cbdnf ko mice lacking all forms of BDNF in neurons exhibit normal LTD 
in acutely prepared hippocampal slices, while LTP induction was significantly 
affected. These results seem to exclude the model in which regulation of 
extracellular conversion of pro-BDNF to mature BDNF controls the extent of 
signaling via p75NTR or TrkB receptors, alternatively promoting LTD or LTP (Lu et 
al., 2005). While our studies focused on endogenous BDNF and intact neurons, it 
allows no prediction to be made as to the processing or the lack of pro-BDNF in 
injured neurons or in other cells. It is well possible that like it has been previously 
shown with NGF (Srinivasan et al., 2004; Harrington et al., 2004) cells such as 
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microglia may release substantial quantities of pro-BDNF after brain injury. 
However, our results also suggest that neurons may only have a limited capacity 
to process endogenous pro-BDNF, which may explain previous results indicating 





4.5.1 Reduction of striatal volume in cbdnf ko mice 
 
In the present study, we examined the role of BDNF in the adult brain by using 
cbdnf ko mice lacking almost completely BDNF in the CNS. The striatum and 
cortex, but not the hippocampus of 2-month old cbdnf ko mice was reduced in 
volume compared with wild-type. We initially examined the possibility that the 
decrease in striatal volume could be explained by cell loss or by a decrease in 
the size of axonal diameter of the cortico-striatal afferents, with a corresponding 
decrease in myelination. However, the absence of BDNF neither caused the loss 
of neurons or of axons, nor were axonal growth and myelination measurably 
affected. Since within different brain regions the ratio of GABAergic and 
glutamatergic neurons varies tremendously, i.e. in the striatum GABAergic 
neurons compromise approximately 95%, in the cortex 20-30% and in the 
hippocampus 5-10%, another explanation for the disproportional reduction in the 
volume of the striatum of 2-month old cbdnf ko mice compared with the 
hippocampus could be that GABAergic neurons are more dependent on BDNF 
for their postnatal growth than is the case for glutamatergic neurons. To test this 
hypothesis, primary cultures of the striatum and the hippocampus  (both wild-
type) will be treated with BDNF, immunostained for GAD and MAP2 and 
subsequently the morphology of pyramidal and non-pyramidal neurons will be 
comparatively analyzed (in collaboration with Dr. Ruben Deogracias). In a 
parallel approach, brain slices of 8 weeks old cbdnf ko mice and wild-type mice 
will be labeled with DiO using a gene gun methodology and the morphology of 
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striatal medium spiny neurons and hippocampal pyramidal neurons will be 
comparatively analyzed (Martin Korte, TU, Braunschweig). 
 
4.5.2 cbdnf ko mice - Model for Huntington´s disease and food intake     
         regulation? 
 
Despite methodological improvements with regard to the delivery of neuro-
trophins, many difficulties still remain, as these molecules have a number of 
suboptimal pharmacological properties, including rapid clearance with a serum 
half-life of minutes or less, poor oral bioavailability, and restricted CNS 
penetration (Poduslo and Curran, 1996; Pardridge, 2002). One potentially 
powerful approach overcoming these limitations is the development of 
neurotrophin mimetics with favourable stability and tissue penetration profiles 
that act via targeted neurotrophin receptors, such as TrkB. Researchers are 
therefore developing small-molecule BDNF analogues with improved 
pharmacokinetic properties and an ability to penetrate the blood brain barrier to 
an appreciable extent. One source of inspiration for these studies is the three-
dimensional structure of BDNF, which has been used as a template to design 
cyclic peptides that mimic BDNF making use of loops 1, 2 and 4, which are 
required for binding to TrkB receptors. Preliminary studies have demonstrated 
that such BDNF mimetics act as BDNF agonists that promote the survival of 
cultured sensory neurons (O’Leary and Hughes, 2003; Fletcher and Hughes, 
2006). As cbdnf ko mice show a shortend life-span and a massive striatal volume 
reduction at 2-month, it would be interesting to test in future studies if treatment 
of cbdnf ko mice with such mimetics extends their lifespan and rescues the 
morphology of the striatum. Likewise, it is conceivable, that antibodies activating 
TrkB may be developed and tested in our cbdnf ko animals, with regard to the 
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4.5.3 cbdnf ko mice – Localization  of pro- and mature BDNF   
 
We showed that in hippocampal neurons pro-BDNF is a transient intermediate 
that is converted intracellularly to the mature form of BDNF, which is stored and 
released by excitatory input (Matsumoto et al., 2008). Recently, Egan et al. 
(2003) demonstrated that the Val66Met substitution in the pro-region of BDNF 
affects the sorting of BDNF into the nerve terminals, retards activity-dependent 
secretion and reduces learning functions of the hippocampus in humans. 
Therefore, detailed knowledge of the subcellular localization of endogenous pro- 
and mature BDNF is becoming increasingly important and would contribute to the 
understanding of the processing of BDNF in cell bodies and/or dendrites. In 
collaboration with my colleagues Drs. Sandra Dieni (Anatomy, Freiburg, 
Germany) and Tomoya Matsumoto, we plan to examine the endogenous 
localization of pro- and mature BDNF in the adult brain. Brain sections of 8 
weeks old wild-type, bdnf-myc and cbdnf ko mice are immunostained for pro- and 
mature BDNF and the subcellular localization of pro- and mature BDNF is 
comparatively analyzed in pyramidal neurons of the hippocampus. 
 
4.5.4 Generation of an inducible BDNFKO mouse by crossing the floxed  
          bdnf mouse line with a tau::CreErt 2 mouse line 
 
The generation of cbdnf ko mice circumvent the problem of postnatal lethality 
and allow a ≥ 95% reduction of BDNF protein levels throughout the brain 
compared with wild-type mice. However, this approach still suffers from the fact 
that tau is expressed very early in development with the consequence that the 
majority of animals generated results in the development of bdnf full knockout 
mice. To investigate the role of BDNF in the adult mouse brain more efficient, we 
are planning to generate a tau::CreERT2 mouse, which may allow us to delete 
BDNF after tamoxifen application. Further studies of these inducible BDNF KO 
mice will hopefully enable a more complete understanding of the role played by 
this neurotrophin in the adult and perhaps even aging brain.  
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